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Abstract	
The	pregnane	X	receptor	(PXR)	is	a	nuclear	receptor	(NR),	involved	in	the	detoxification	of	xenobiotic	compounds.	Recently,	its	presence	was	reported	in	the	human	vasculature	and	 its	 ligands	 were	 proposed	 to	 exhibit	 anti-atherosclerotic	 effects.	 Since	 platelets	contribute	towards	the	development	of	atherosclerosis	and	possess	numerous	NRs,	we	investigated	 the	 expression	 of	 PXR	 in	 platelets	 along	with	 the	 ability	 of	 its	 ligands	 to	modulate	platelet	activation.	The	expression	of	PXR	in	human	platelets	was	confirmed	using	 immunoprecipitation	analysis.	Treatment	with	PXR	 ligands	was	 found	 to	 inhibit	platelet	 functions	stimulated	by	a	range	of	agonists,	with	platelet	aggregation,	granule	secretion,	adhesion	and	spreading	on	fibrinogen	all	attenuated	along	with	a	reduction	in	thrombus	formation	(both	in	vitro	and	in	vivo).	The	effects	of	PXR	ligands	were	observed	in	a	species-specific	manner,	and	the	human-specific	ligand,	SR12813,	was	observed	to	attenuate	 thrombus	 formation	 in	 vivo	 in	humanised	PXR	 transgenic	mice.	PXR	 ligand-mediated	inhibition	of	platelet	function	was	found	to	be	associated	with	the	inhibition	of	Src-family	kinases	(SFKs).	This	study	identifies	acute,	non-genomic	regulatory	effects	of	PXR	 ligands	 on	 platelet	 function	 and	 thrombus	 formation.	 In	 combination	 with	 the	emerging	 anti-atherosclerotic	 properties	 of	 PXR	 ligands,	 these	 anti-thrombotic	 effects	may	provide	additional	cardio-protective	benefits.	
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Introduction	Nuclear	 receptors	 (NRs)	 are	 well	 characterised	 for	 their	 genomic	 functions	(transcriptional	 regulation),	 however,	 less	 is	 known	 about	 their	 non-genomic	 roles.	Several	 NRs	 (such	 as	 LXR,	 PPARα/β/γ,	 RXR,	 RAR	 and	 FXR)	 have	 been	 identified	 in	platelets,	 which	 upon	 ligation	 regulate	 platelet	 activity,	 thrombosis	 and	 haemostasis	through	a	variety	of	mechanisms	in	a	non-genomic	manner1-7.	The	pregnane	X	receptor	(PXR)	forms	a	heterodimer	with	retinoid	X	receptor	(RXR)8	and	functions	as	a	sensor,	activated	by	xenobiotic	and	toxic	endogenous	compounds,	leading	to	their	metabolism	and	 elimination	 through	 the	 upregulation	 of	 cytochrome	 P450	 enzymes.	 PXR	 is	predominantly	expressed	in	liver	and	intestines9	and	unlike	other	NRs,	displays	a	large	and	flexible	ligand-binding	domain	(LBD)	that	enables	its	binding	with	a	diverse	array	of	ligands	 that	 includes	 bile	 acids,	 pharmaceutical	 substrates,	 herbal	 medicines,	environmental	 pollutants,	 and	 endobiotics10.	 Additionally,	 the	 LBD	 of	 PXR	 shows	variation	 in	amino	acid	sequence	amongst	different	 species11.	Therefore,	 inter-species	differences	 in	 the	 ligands	 that	activate	PXR	have	been	reported.	Consequently,	human	PXR	 is	activated	by	 ligands	such	as	SR12813	and	rifampicin,	whilst	 they	do	not	affect	mouse	 PXR.	 Similarly,	 the	 PXR	 ligand,	 pregnenolone	 16α-carbonitrile	 (PCN),	 is	 highly	specific	to	rodents	only12,13.	Increasing	 evidence	 identifies	 PXR	 to	 act	 as	 a	 potential	 therapeutic	 target	 for	 the	treatment	 of	 a	 variety	 of	 patho-physiologies14.	 PXR	 ligands	 have	 demonstrated	 anti-atherosclerotic	 effects	 via	 increased	 cholesterol	 clearance	 and	 HDL	 production	 in	 a	mouse	model	of	atherosclerosis15-17.	Recently,	PXR	was	reported	to	be	expressed	in	the	human	vasculature	(blood	vessels,	aortic	endothelial	and	smooth	muscle	cells),	where	it	functions	to	detoxify	circulating	toxins	and	avert	vascular	damage	by	upregulating	CYP	3A,	2B	and	2C	activity18.		
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Here,	we	report	the	presence	of	PXR	in	human	platelets.	Treatment	of	platelets	with	PXR	ligands	(SR12813	or	rifampicin)	attenuated	platelet	functions	and	thrombus	formation	(in	vitro	and	in	vivo)	through	a	mechanism	that	is	associated	with	the	down-regulation	of	Src-family	kinase	(SFKs)	signalling.		
	
Materials	and	Methods	
Reagents.	 Bovine	 thrombin,	 rifampicin	 and	 5-Pregnen-3β-ol-20-one-16α-carbonitrile	(PCN)	were	purchased	from	Sigma-Aldrich.	Collagen	was	obtained	from	Nycomed.	CRP-XL	was	from	Professor	R.	Farndale	(University	of	Cambridge).	SR12813	was	from	Abcam	(Cambridge,	 UK).	 Primary	 polyclonal	 anti-PXR	 (sc25381),	 monoclonal	 anti-RXRα/β/γ	(sc46659),	14-3-3	ζ	 (sc-293415)	and	actin	(sc-1615)	antibodies	were	 from	SantaCruz.	Monoclonal	 anti-PXR	 (ab41930),	 primary	 phospho	 anti-Lyn	 (Y396)	 (ab226778),	 Syk	(Y525/526)	 (ab58575)	 and	 LAT	 (Y200)	 (ab68139)	 antibodies	 were	 from	 Abcam.	Primary	phospho	anti-Src	(Y418)	(#44-660G)	was	from	ThermoFisher	Scientific.	Primary	phospho	anti-PLCγ2	(Y1217)	(#3871),	VASP	(S157	and	S239)	(#3111	and	#3114)	and	PKC	(#2261)	were	purchased	from	Cell	Signalling	Technologies.	Anti-phospho-Tyr	4G10	(#05-321)	antibody	was	from	Millipore.	Fluorophore	conjugated	secondary	antibodies,	Fura-2AM	 and	 Alexa-488	 conjugated	 phalloidin	 were	 from	 Life	 Technologies.	 PE-Cy5	anti-CD62P	antibody	was	from	BD	Biosciences.	FITC-labelled	anti-fibrinogen	was	from	Dako.	 All	 other	 reagents	 were	 from	 previously	 described	 sources5,6.	 Humanised	 PXR	transgenic	mice	[C57BL/6-Nr1i2tm1(NR1I2)Arte]	were	purchased	from	Taconic	Biosciences	(Denmank)	and	bred	under	licence	at	the	bioresource	unit	of	the	University	of	Reading.		
Human	 blood	 collection.	 Blood	 was	 collected	 with	 approval	 by	 the	 University	 of	Reading	 Research	 Ethics	 Committee,	 and	 in	 accordance	 with	 the	 Declaration	 of	
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Helsinki.	 Human	 blood	 was	 collected	 in	 3.8%	 (v/v)	 citrate	 by	 venepuncture	 from	aspirin	 free,	 healthy	 volunteers	 after	 obtaining	 their	 informed	 consent.	 Detailed	method	is	available	in	the	supplementary	information.	All	methods	performed	in	the	study	were	carried	out	 in	accordance	with	 the	University	of	Reading	guidelines	and	regulations	 concerning	 ethical	 approval,	 health	 and	 safety,	 the	 use	 of	 animals	 in	experimentation	 and	 research	 quality	 assurance.	 Experimental	 protocols	 were	approved	 by	 the	 University	 of	 Reading	 Research	 Ethics	 Committee	 and	 the	 Animal	Welfare	 Ethical	 Review	 Board.	 Experiments	 using	 animals	 were	 approved	 and	performed	in	accordance	with	a	licence	issued	by	the	UK	Home	Office	
	
Platelet	 preparation,	 aggregation	 and	 dense	 granule	 secretion	 assays.	 Platelet	aggregation	 and	 dense	 granule	 secretion	 in	 washed	 platelets	 was	 determined	 using	lumiaggregometry	by	measuring	changes	in	optical	density	and	ATP	release,	respectively.	Detailed	method	is	available	in	the	supplementary	information.	
	
Immunofluorescence	 microscopy.	 Human	 (in	 PRP)	 stimulated	 with	 or	 without	thromboxane	 A2	 receptor	 agonist,	 U46619	 (5µM),	were	 left	 to	 settle	 on	 poly-L-lysine	coverslips	for	1	hour	at	37°C	before	permeabilisation	and	blocking	(0.2%	Triton-X-100,	1%	BSA,	2%	donkey	serum).	Coverslips	were	 then	 incubated	with	primary	antibodies	(PXR	or	RXR	and	GPIb)	overnight	(4°C)	and	washed	in	PBS	before	staining	with	Alexa-fluor	conjugated	secondary	antibodies	 for	1	hour	at	room	temperature.	Platelets	were	imaged	on	a	Nikon	A1-R	confocal	microscope	(100X	magnification	oil	immersion	lens).	Detailed	method	is	available	in	the	supplementary	information.		
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Immunoblotting	 and	 immunoprecipitation.	 Washed	 platelets	 (4×108	 or	 8×108	cells/ml)	were	lysed	in	an	equal	volume	of	NP40	buffer	(300mM	NaCl,	20mM	Tris	base,	2mM	EGTA,	2mM	EDTA,	1mM	PMSF,	10µg/ml	aprotinin,	10µg/ml	 leupeptin,	0.7µg/ml	pepstatin	A,	2mM	sodium	orthovanadate,	2%	NP-40,	pH	7.3),	 and	proteins	of	 interest	were	isolated	using	1μg/mL	of	appropriate	antibodies.	Detailed	method	is	available	in	the	 supplementary	 information.	 Immunoblotting	 was	 performed	 using	 standard	techniques	as	described	 in	 the	 supplementary	 information.	Levels	of	phosphorylated	proteins	 were	 detected	 using	 fluorophore-conjugated	 secondary	 antibodies	 and	visualised	using	a	Typhoon	FLA	9500	(GE	healthcare)	and	quantified	using	Image	Quant	software	version	8.1	(GE	healthcare).	Protein	loading	was	assessed	through	reprobing	for	actin	or	14-3-3ζ.		
Fibrinogen	binding	and	alpha	granule	secretion.	Activation	of	the	integrin	αIIbβ3	and	alpha-granule	secretion	were	measured	by	measuring	levels	of	fibrinogen	binding	and	P-selectin	exposure	on	the	platelet	surface	by	flow	cytometry	using	FITC-conjugated	anti-fibrinogen	and	PE/Cy5-labelled	anti-CD62P	antibody,	respectively.	Using	a	BD	Accuri	C6	flow	cytometer,	10,000	events	were	analysed	using	the	CFlow	Sampler	software.	Detailed	methods	for	both	are	available	in	the	supplementary	information.	
	
Calcium	mobilisation.	PRP	was	loaded	with	Fura-2	AM	(2µM)	for	1h	at	30oC	and	then	washed	platelets	were	prepared.	Fura-2AM-loaded	platelets	were	 incubated	with	PXR	ligands	or	 vehicle	prior	 to	 their	 activation.	The	 ratio	of	 emission	values	 (excitation	at	340/380	nm)	was	recorded	using	a	NOVOstar	plate	reader	(BMG	Labtech)	and	converted	to	 calcium	 concentration.	 Detailed	 method	 is	 available	 in	 the	 supplementary	information.	
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Platelet	 spreading	 and	 clot	 retraction.	Washed	 human	 platelets	 (2x107	 cells/ml)	treated	with	or	without	PXR	ligands	were	exposed	to	fibrinogen	or	collagen	(100µg/ml)	coated	 coverslips	 for	 45	 minutes.	 Adhered	 platelets	 were	 fixed	 using	 2%	 (v/v)	paraformaldehyde	 and	 permeabilised	 with	 0.2%	 (v/v)	 Triton-X-100.	 Thereafter,	platelets	were	 stained	 using	Alexa488-conjugated	 phalloidin.	 Adherent	 platelets	were	imaged	on	a	Nikon	A1-R	confocal	microscope	(100X	magnification	oil	immersion	lens).	The	number	of	platelets	in	different	stages	of	spreading	were	obtained	by	counting,	for	each	sample,	the	number	of	platelets	in	5	randomly	chosen	fields	of	view.	Clot	retraction	was	studied	in	thrombin	(1	U/mL)	stimulated	PRP	treated	with	or	without	PXR	ligands	for	a	period	of	1	hour	(37°C).	Clot	weight	was	measured	as	a	marker	of	clot	retraction.	Detailed	methods	are	available	in	the	supplementary	information.		
Thrombus	 formation	 in	 vitro.	 Human	 or	 mouse	 blood	 fluorescently	 labelled	 with	lipophilic	dye	DIOC6	was	pre-incubated	with	vehicle	or	PXR	ligands	and	perfused	over	a	collagen-coated	 (100	µg/ml)	microfluidic	biochip	 (Cellix)	 at	 an	arterial	 shear	 rate	 (20	dyn/cm2).	 Images	 of	 thrombi	 were	 obtained	 using	 a	 using	 Nikon	 A1-R	 Confocal	microscope	(20X	objective)	and	fluorescence	intensity	was	calculated.	Detailed	method	is	available	in	the	supplementary	information.		
Thrombus	formation	in	vivo	and	tail	bleeding	assay.	Thrombosis	in	humanised	PXR	transgenic	 mice	 (hPXR)	 treated	 with	 SR12813	 or	 vehicle	 that	 were	 administered	intravenously	was	assayed	following	laser-induced	injury	by	intravital	microscopy.	After	laser-induced	 injury	of	 the	 inner	wall	of	 cremaster	muscle	arterioles,	 accumulation	of	platelets	was	 assessed.	 Fluorescence	 and	 bright-field	 images	were	 recorded	 using	 an	Olympus	BX61W	microscope	with	a	60X/1.0	NA	water	immersion	objective	and	a	high-
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speed	 camera.	 Data	 was	 analysed	 using	 Slidebook5	 software	 (Intelligent	 Imaging	Innovations).	Tail	bleeding	experiments	following	removal	of	the	tail-tip	were	performed	on	20–25g	hPXR	mice,	anesthetized	with	ketamine	(100mg/kg)	and	xylazine	(10mg/kg)	injected	 intraperitoneally.	 Detailed	 methods	 are	 available	 in	 the	 supplementary	information.	
	
Statistical	 analysis.	 Data	 were	 analysed	 using	 ANOVA	 with	 Bonferroni	 post-test	 as	indicated,	or	where	appropriate	by	t-test.	The	Mann-Whitney	U	test	was	used	to	analyse	tail	bleeding	and	thrombosis	assay.	Data	represent	mean±SD	and	P˂0.05	was	considered	to	be	statistically	significant.	Statistical	analysis	was	performed	using	GraphPad	Prism	7.0	software	(California,	USA).		
	
Results	
PXR	is	present	in	human	platelets.	Initial	analysis	of	platelet	lysates	for	the	presence	of	 PXR	 revealed	 a	 weak	 band	 of	 the	 receptor.	 Therefore,	 immunoprecipitation	 was	performed	 to	 enrich	 the	 sample	 with	 PXR	 to	 enhance	 its	 detection.	 The	 protein	 was	immunoprecipitated	 from	platelet	 lysates using	a	mouse	anti-PXR	antibody	 (targeting	amino	acids	1-40)	and	its	presence	was	confirmed	by	immunoblotting	with	a	rabbit	anti-PXR	antibody	(targeting	amino	acids	101-260)	(Fig.	1A).	The	sub-cellular	localisation	of	PXR	was	studied	in	resting	human	platelets	using	immunofluorescence	microscopy.	The	PXR	(red	stain)	was	noted	to	be	distributed	inside	the	platelet	cytosol	(green	stain	marks	platelet	 surface	 GPIb)	 in	 a	 punctate	 arrangement	 (Fig.	 1B).	 Previously,	 it	 has	 been	reported	 that	 NRs	 such	 as	 RXR	 and	 PPARg	 are	 secreted	 from	 platelets	 upon	 their	activation19.	This	was	evaluated	 for	PXR	 in	resting	and	activated	 (0.1	U/ml	 thrombin)	
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permeabilised	platelets	using	flow	cytometry.	The	level	of	fluorescence	associated	with	PXR	in	thrombin-activated	platelets	was	reduced,	in	comparison	with	resting	platelets,	suggesting	 a	 reduction	 in	 the	 number	 of	 PXR	molecules	 present	 inside	 the	 activated	platelets,	consistent	with	release	or	secretion	(Fig.	1C,	1D).			
PXR	 and	 RXR	 exists	 as	 heterodimers	 in	 human	 platelets.	 The	 formation	 of	heterodimers	between	RXR	and	other	NRs	(PPAR’s,	FXR,	PXR,	LXR)	in	nucleated	cells	is	known20	and	our	previous	work	suggested	 the	existence	of	RXR-LXR,	RXR-PPARα	and	RXR-PPARγ	heterodimers	in	human	platelets6.	The	potential	ability	for	PXR	to	interact	with	 RXR	 in	 platelets	 was	 therefore	 examined.	 RXR	 and	 PXR	 were	 found	 to	 co-immunoprecipitate	 in	 both	 resting	 and	 activated	 platelets	 (Fig.	 2A).	 Using	immunofluorescence	microscopy,	a	high	degree	of	colocalisation	between	RXR	(red)	and	PXR	(blue)	was	observed	in	both	resting	(Fig.	2B)	and	U46619-activated	(5	µM)	(Fig.	2B)	platelets	(stained	in	green	for	GPIb).	A	scatter	plot	demonstrated	a	clear	relationship	of	fluorescence	intensity	points	for	RXR	and	PXR,	clustering	proportionally	along	a	straight	line	(approximately	45	degrees	to	either	axis),	indicating	a	high	level	of	colocalisation	in	resting	and	activated	platelets	(Fig.	2C).	In	alignment	with	this,	the	Pearson’s	correlation	coefficient	(PCC),	was	 found	to	be	0.94	and	0.92	between	RXR	and	PXR	in	resting	and	activated	platelets,	respectively,	indicating	a	strong	co-localisation.	There	was	no	change	in	the	extent	of	PXR-RXR	colocalization	between	resting	and	activated	platelets	(Fig.	2D).		
PXR	ligands	inhibit	platelet	aggregation	to	a	range	of	platelet	activators.	The	effects	of	 two	 structurally	distinct	PXR	 ligands,	 SR12813	and	 rifampicin10	were	evaluated	on	platelet	aggregation,	stimulated	by	various	platelet	activators.	To	maintain	consistency	in	 results,	 the	 concentration	of	 each	platelet	 agonist	 for	 each	donor	was	optimized	 to	
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attain	 50%	 maximal	 aggregation	 (EC50)	 in	 5	 minutes.	 Treatment	 of	 platelets	 with	SR12813	for	10	minutes	reduced	platelet	aggregation	mediated	by	collagen	(EC50:	0.5-0.8	μg/ml)	by	27%	and	40%	at	50	and	100	μM	SR12813	(Fig.	3A),	respectively,	compared	to	vehicle	 (DMSO	 0.1%	 v/v).	 Similar	 levels	 of	 inhibition	were	 observed	with	 rifampicin	treatment	 (Suppl.	 Fig.	 1A).	 Increasing	 the	 incubation	 period	 of	 SR12813	 (Fig.	 3B)	 or	rifampicin	(Suppl.	Fig.	1B)	to	20	minutes	strongly	enhanced	inhibition	against	collagen-stimulation,	 which	 may	 reflect	 the	 rate	 of	 transit	 of	 PXR	 ligands	 across	 the	 plasma	membrane.	 Aggregation	mediated	 by	 the	 G	 protein–coupled	 receptor	 (GPCR)	 agonist	thrombin	(EC50:	0.03-0.04	U/ml)	was	also	attenuated	by	SR12813	or	rifampicin	(10-mins	incubation).	 50	 and	 100	 μM	 of	 SR12813	 demonstrated	 35%	 and	 42%	 reduction	 in	aggregation	respectively	at	3-minute	post-activation	by	thrombin	in	comparison	with	5-minutes	 interval,	 which	 was	 around	 15%	 and	 23%,	 respectively	 (Fig.	 3C).	 Similar	observations	were	made	with	rifampicin	(Suppl.	Fig.	1C).	In	addition	to	this,	both	the	PXR	ligands	inhibited	U46619-mediated	platelet	aggregation	(EC50	range:	0.2-0.4	μM)	(Suppl.	Fig.	1D,	1E)	and	ADP	(EC50	range:	5-10μM)	(Suppl.	Fig.	1F,	1G),	indicating	that	the	effects	of	 PXR	 ligands	 are	 widespread	 (acting	 on	 both	 GPVI	 and	 GPCR-mediated	 platelet	activation)	and	not	restricted	to	a	specific	platelet	activation	pathway.				
PXR	 ligands	 inhibit	 integrin	αIIbβ3	activation	and	platelet	 secretion.	The	affinity	upregulation	 of	 integrin	 αIIbβ3	 following	 platelet	 activation	 is	 essential	 for	 platelet	aggregation.	Therefore,	 the	effects	of	PXR	 ligands	on	 the	extent	of	CRP-XL	 (EC50:	0.25	µg/ml)	or	thrombin	(EC50:	0.05	U/ml)	induced	fibrinogen	binding	to	integrin	αIIbβ3	were	evaluated	in	PRP	using	flow	cytometry.	In	alignment	with	reduced	aggregation,	CRP-XL-induced	fibrinogen	binding	was	inhibited	by	52%	at	100	μM	SR12813,	in	comparison	to	vehicle-control	(DMSO	0.1%	v/v)	(Fig.	3D).	Thrombin-stimulated	fibrinogen	binding	was	
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also	attenuated	by	100	µM	SR12813	by	40%	(Fig.	3E).	Similar	effects	were	demonstrated	by	 rifampicin	 on	 CRP-XL	 or	 thrombin	 stimulation	 (Suppl.	 Fig.	 2A).	 To	 investigate	 the	effects	of	PXR	ligands	on	degranulation,	the	extent	of	alpha	and	dense	granules	secretion	was	evaluated	by	measuring	P-selectin	exposure	on	the	platelet	surface	and	ATP	release,	respectively.	SR12813	(Fig.	3F,	3G)	and	rifampicin	(100	μM)	(Suppl.	Fig.	2B)	caused	40%	and	 30%	 reduction	 in	 CRP-XL	 (0.25	 µg/ml)	 or	 thrombin-stimulated	 (0.05	 U/ml)	 P-selectin	 exposure,	 respectively,	 compared	 to	 vehicle	 (DMSO	 0.1%	 v/v).	 ATP	 release	following	 stimulation	 by	 either	 collagen	 (1	 µg/ml)	 or	 thrombin	 (0.05	U/ml)	was	 also	attenuated	following	pre-treatment	of	platelets	with	SR12813	(Fig.	3H,	3I)	or	rifampicin	(Suppl.	Fig.	2C,	2D).	
In	addition	to	degranulation,	activated	platelets	synthesise	TxA2	from	arachidonic	acid	through	the	actions	of	COX-1	and	TxA2	synthase.	TxA2	synthesis	and	release	activate	more	platelets	 at	 the	 site	 of	 injury,	 thus,	 amplifying	 the	 aggregation	 response.	 SR12813	treatment	significantly	down-regulated	both	CRP-XL	(1	μg/ml)	or	thrombin	(0.05	U/ml)	evoked	TxB2	(a	stable	metabolite	of	TxA2)	production	by	washed	platelets	(Fig.	3J,	3K).	Higher	concentrations	of	platelet	agonists	were	used	to	ensure	maximum	secretion	and	synthesis	of	ATP	and	TxB2	from	activated	platelets	for	effective	detection.	Consequently,	incubation	time	with	PXR	ligands	was	prolonged	(20	mins)	in	these	assays.		
Collagen-evoked	 platelet	 aggregation	 depends	 partially	 on	 the	 release	 of	 secondary	mediators.	Since	PXR	ligands	can	inhibit	aggregation	instigated	by	both	ADP	and	U46619,	we	 investigated	 whether	 the	 inhibitory	 effects	 of	 PXR	 ligands	 against	 collagen-stimulation	 (10	µg/ml)	are	 independent	of	 their	ability	 to	 reduce	secondary	mediator	effects.	Given	the	high	concentration	of	collagen	used	in	this	assay,	SR12813	(100	µM)	on	its	own	did	not	affect	platelet	aggregation	(Suppl.	Fig.	2E),	however,	the	inhibitory	effects	
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of	SR12813	(100	µM)	were	found	to	be	additive	to	the	inhibition	caused	by	saturating	concentrations	of	secondary	mediator	inhibitors;	indomethacin	(20	µM;	TxA2	synthesis	blocker)	 and	ADP	 receptor	 antagonists	 (1	 µM	 cangrelor	 and	 100	 µM	MRS2179).	 This	indicates	that	the	effects	of	SR12813	on	collagen-mediated	platelet	aggregation	are	not	solely	dependent	on	its	effects	on	secondary	mediators	released	during	activation	(Suppl.	Fig.	2E).		
	
Species-specific	 effects	and	 inhibition	of	 thrombus	 formation	 in	vitro	by	human	
and	mouse	PXR	ligands.	As	mentioned	earlier,	a	dissimilarity	exists	in	the	sequence	of	PXRs	LBD	between	species,	with	only	76%	amino	acid	sequence	similarity	 in	 the	LBD	between	 human	 and	 mouse	 PXR10.	 This	 results	 in	 a	 high	 degree	 of	 inter-species	differences	in	ligands	that	activate	PXR.	This	property	was	explored	to	assess	whether	the	effects	of	PXR	 ligands	are	 likely	to	be	mediated	through	binding	to	PXR	protein	 in	platelets.	Consequently,	the	effects	of	human	(SR12813)	or	mouse	(PCN)	PXR	ligands	on	CRP-XL-stimulated	fibrinogen	binding	in	human	and	mouse	platelets	were	investigated.	It	was	not	possible	to	directly	compare	the	responses	of	human	and	mouse	platelets	as	their	activation	profile	 is	quite	different	towards	the	similar	concentrations	of	platelet	agonists.	For	instance,	a	concentration	of	0.25	μg/ml	of	CRP-XL	was	sufficient	to	activate	human	 platelet	 samples	 to	 study	 the	 effects	 of	 human	 PXR	 ligands,	 however,	 this	produced	a	modest	effect	on	mouse	platelets.	Consequently,	 the	CRP-XL	concentration	was	enhanced	to	0.5	μg/ml	for	experiments	using	mouse	PRP.	In	comparison	to	vehicle-control	(DMSO	0.1%	v/v),	100	μM	of	SR12813	reduced	CRP-XL-stimulated	(0.25	μg/ml)	fibrinogen	binding	in	human	platelets	by	50%	(Fig.	3D).	However,	SR12813	did	not	cause	any	change	in	mouse	platelet	responses	stimulated	with	CRP-XL	(0.5	μg/ml)	(Fig.	4A).	Similarly,	mouse	PXR	ligand,	PCN	(100	μM),	inhibited	CRP-XL-evoked	fibrinogen	binding	
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in	mouse	platelets	by	25%	in	comparison	to	vehicle-control	(DMSO	0.5%	v/v),	whereas,	no	effect	was	observed	in	human	platelets	(Fig.	4B).	These	findings	not	only	demonstrate	species-specific	effects	of	PXR	ligand	but	also	provides	evidence	that	the	effects	of	PXR	ligands	are	mediated	via	PXR	in	human	and	mouse	platelets.	
Given	the	ability	of	PXR	ligands	to	regulate	numerous	aspects	of	platelet	activation,	we	investigated	their	implications	on	thrombus	formation	in	vitro.	Treatment	with	SR12813	(100	µM)	for	20-minutes	inhibited	thrombus	development	in	contrast	to	vehicle	(DMSO	0.1%	v/v)	 (Fig.	 4C).	 Rifampicin	 (100µM)	 treatment	 also	 reduced	 thrombus	 formation	(Suppl.	 Fig.	 3A).	 Furthermore,	 the	 initial	 kinetics	 of	 thrombus-development	 in	 PXR	ligand-treated	samples	were	inhibited	in	comparison	to	vehicle-control,	which	might	be	due	to	reduced	adhesion	of	platelets	to	collagen.	
The	thrombus	formation	assay	was	also	performed	to	study	the	species-specific	effects	of	PXR	 ligands.	 In	 comparison	 to	 vehicle	 (DMSO	 0.5%	 v/v),	 20-minutes	 treatment	 with	mouse	PXR	 ligand,	 PCN	 (100	μM),	 caused	 a	 50%	 reduction	 in	 thrombus	 formation	 in	mouse	blood	(Fig.	4E).	In	contrast,	thrombus	formation	in	PCN	(100	μM)	treated	human	blood	was	not	 altered	 (Fig.	4F).	To	 further	 confirm	 the	 species-specific	nature	of	PXR	ligands,	 the	 effect	 of	human	PXR	 ligand	 (SR12813)	was	 evaluated	 in	mouse	blood.	As	discussed	previously,	SR12813	reduced	thrombus	formation	in	human	blood	(Fig.	4C),	but	thrombus	development	in	mouse	blood	treated	with	SR12813	was	similar	to	vehicle-treated	samples	(Fig.	4D).		
PXR	 ligands	 inhibit	 thrombosis	 and	 haemostasis	 in	 mice.	 Given	 the	 negative-regulation	 of	 thrombus	 formation	 in	 vitro,	 the	 acute	 effect	 of	 human	 PXR	 ligand	(SR12813)	 was	 evaluated	 in	 vivo.	 As	 explained	 earlier,	 PXR	 ligands	 exhibit	 species-
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specific	 responses	 in	 platelets;	 therefore,	 the	 effects	 of	 SR12813	 were	 studied	 on	humanised	 PXR	 transgenic	 mice	 (hPXR).	 These	 mice	 lack	 the	 endogenous	 PXR	 gene,	which	is	replaced	with	human	PXR	gene	and	is	reported	to	be	responsive	towards	human	PXR	ligands	and	not	to	mouse	PXR	ligand21-24.	Prior	to	the	investigation,	the	expression	levels	of	integrin	α2β1,	αIIbβ3,	GPIb	and	GPVI	(Suppl.	Fig.	3B,	3C,	3D,	3E)	receptors	on	hPXR	were	compared	with	background	C57BL/6	mice	and	were	found	to	be	similar.			
	The	 acute	 effects	 of	 PXR	 ligands	 on	 in	 vivo	 thrombus	 formation	 were	 evaluated	 by	studying	laser-induced	thrombosis	in	mouse	cremaster	muscle	arterioles.	As	shown	in	Fig.	5A,	the	initial	kinetics	of	thrombus	formation	in	SR12813	(100	µM)	treated	mice	was	similar	to	vehicle	(DMSO	0.1%	v/v)	(Fig.	5B),	however,	the	overall	size	of	thrombi	was	substantially	reduced	by	80%	(Fig.	5C).	Moreover,	maximum	fluorescence	 intensity	of	thrombus	was	reduced	by	45%	in	SR12813	treated	mice,	consistent	with	the	formation	of	 smaller	 thrombi	 (Fig.	 5D).	 Together	 these	 results	 suggest	 PXR	 ligands	 elicit	 anti-thrombotic	 effects.	 We	 cannot	 exclude	 the	 effects	 of	 other	 cell	 types	 on	 thrombosis,		although	the	level	of	inhibition	in	the	presence	of	SR12813	was	comparable	to	its	ability	to	attenuate	thrombus	formation	in	vitro,	assays	where	vasculature	or	endothelial	cells	are	 not	 present.	 This	 suggests	 that	 PXR-mediated	 down-regulation	 of	 thrombus	formation	might	be	independent	of	the	effects	from	other	vascular	cell	types.	
Given	the	observed	anti-thrombotic	properties	of	PXR	ligands,	the	effect	of	SR12813	on	haemostasis	was	measured	by	a	tail-bleeding	assay	performed	on	hPXR	mice.	The	mean	time	 to	 cessation	 of	 bleeding	 was	 prolonged	 to	 approximately	 500	 seconds	 in	 mice	treated	with	SR12813,	in	comparison	vehicle-treated	mice	(275	seconds),	demonstrating	that	acute	PXR	ligand	treatment	 increases	bleeding	and	impairs	haemostasis	(Fig.	5E).	The	tail-bleeding	assay	takes	into	account	both	platelet-function	and	and	the	coagulation	
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processes25-27	and	therefore,	besides	the	effects	of	PXR	ligands	on	platelet	activation,	the	effects	of	PXR	ligands	on	coagulation	cannot	be	excluded.		
	
PXR	 ligands	 inhibit	 outside-in	 signalling.	 Binding	 of	 fibrinogen	 to	 integrin	 αIIbβ3	initiates	 outside-in	 signalling	 in	 platelets,	which	 facilitates	 platelet	 spreading	 and	 clot	retraction,	required	for	the	stability	of	the	thrombus.	Given	the	ability	of	PXR	ligands	to	inhibit	events	associated	with	inside-out	signalling	such	as	aggregation,	integrin	αIIbβ3	upregulation	 and	 degranulation,	 their	 effects	 on	 outside-in	 signalling	 were	 also	evaluated.	In	comparison	to	vehicle,	fewer	platelets	were	observed	adhered	to	fibrinogen	(in	45	minutes)	following	20-minutes	treatment	with	SR12813	(50	or	100	μM)	(Fig.	6A).	Additionally,	SR12813	was	also	found	to	hinder	platelet	spreading	with	fewer	platelets	forming	 lamellipodia	 and	 increased	 numbers	 of	 cells	 remaining	 at	 the	 adhered	 or	filopodial	phases	(Fig.	6A).	Similar	observations	were	noted	with	rifampicin	treatment	(Suppl.	Fig.	4A).	Consistent	with	this,	an	increase	in	clot	weight	(indicative	of	reduced	clot	retraction,	 a	 process	 driven	by	 integrin	αIIbβ3	outside-in	 signalling)	was	 observed	 in	samples	treated	with	SR12813	(Fig.	6B)	or	rifampicin	(Suppl.	Fig.	4B)	after	90	minutes,	compared	to	vehicle-treated	samples.	These	data	along	with	previous	findings	suggest	the	ability	of	PXR	ligands	to	modulate	bi-directional	signalling	transmitted	via	integrin	αIIbβ3.		
To	test	whether	the	reduced	adhesion	and	spreading	were	restricted	to	the	functions	of	integrin	αIIbβ3,	similar	experiments	were	performed	on	collagen	(which	is	dependent	on	integrin	α2β1	and	GPVI).	Platelet	adhesion	and	spreading	on	collagen	was	also	found	to	be	 inhibited	with	 SR12813	 (Fig.	 6C)	 and	 rifampicin	 (Suppl.	 Fig.	 4C)	 treatment.	 These	findings	along	with	observations	of	reduced	thrombus	formation	(in	vitro)	suggest	that	
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PXR	 ligand-mediated	 reduction	 in	 thrombus	 formation	 might	 be	 partly	 due	 to	 the	diminished	platelet	adhesion	to	collagen.			
PXR	 ligands	 inhibit	 GPVI-mediated	 signalling	 pathway.	 Having	 identified	 anti-thrombotic	effects	of	PXR	ligands,	we	determined	the	mechanism	by	which	PXR	ligands	elicit	anti-platelet	activity.	We	and	others	have	previously	described	the	involvement	of	NRs	in	the	regulation	of	platelet	inhibitory	signalling	pathways,	notably	activation	of	the	cGMP/PKG	and	cAMP/PKA	linked	pathways1,4,6.	To	determine	whether	PXR,	which	we	have	shown	heterodimerises	with	RXR	(which	regulates	PKA	activity)6	acts	in	a	similar	manner,	VASP	S157		and	VASP	S239,	markers	of	PKA	and		PKG	activity	respectively,	were	determined	 in	PXR	 ligands	 treated	platelets.	 	Neither	of	 the	PXR	 ligands	was	 found	 to	activate	PKA	(Suppl.	Fig.	5A,	5B)	or	PKG	(Suppl.	Fig.	5C,	5D)	activity,	indicating	that	PXR	negatively	 regulates	 platelet	 function	 independently	 of	 these	 inhibitory	 signalling	pathways.		
Since	 PXR	 ligands	 were	 observed	 to	 attenuate	 collagen/CRP-XL-mediated	 platelet	activation,	their	effects	on	the	GPVI-signalling	pathway	were	investigated.	Platelets	were	stimulated	 for	 90	 seconds	 under	 non-aggregating	 conditions	 [EGTA	 (1mM),	indomethacin	(20µM),	cangrelor	(1µM)	and	MRS2179	(100µM)]	to	block	signalling	via	secondary	mediators	 and	 ensure	 the	 study	 of	 primary	 GPVI-signalling.	 Consequently,	CRP-XL	concentration	was	increased	(1	µg/ml)	to	visualise	the	phosphorylation	of	GPVI-signalling	 components	 by	 immunoblot	 analysis6.	 Consistent	 with	 our	 earlier	observations,	pre-treatment	of	platelets	(20-minutes)	with	50	and	100	µM	of	SR12813	(Fig.	7A)	or	rifampicin	(Suppl.	Fig.	6A)	significantly	reduced	CRP-XL-evoked	total	tyrosine	phosphorylation	in	comparison	to	vehicle	(DMSO	0.1%	v/v).	Significant	attenuation	of	
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early	 GPVI-signalling	 events,	 specifically	 phosphorylation	 of	 Syk	 (at	 its	 auto-phosphorylation	site	Y525/526)	by	SR12813	(Fig.	7B)	or	rifampicin	(Suppl.	Fig.	6B)	was	also	 observed.	 Following	 this,	 CRP-XL-stimulated	 phosphorylation	 of	 Linker	 for	Activation	of	T	cells	(LAT)	at	site	Y200	was	also	down-regulated	by	SR128123	(Fig.	7C)	or	 rifampicin	 (Suppl.	 Fig.	 6C)	 treatment	 along	 with	 the	 inhibition	 of	 PLCγ2	phosphorylation	level	(Fig.	7D)	(Suppl.	Fig.	6D)	at	Y1217.		
As	 expected,	 PLCγ2-dependent	 downstream	 processes	 such	 as	 calcium-mobilisation	were	inhibited	by	both	SR1813	(Fig.	7E)	and	rifampicin	(Suppl.	Fig.	6E)	treatment,	along	with	the	reduction	of	protein	kinase	C	(PKC)	phosphorylation	(Fig.	7F)	(Suppl.	Fig.	6F),	both	 of	 which	 are	 essential	 for	 the	 regulation	 of	 cytoskeletal	 rearrangement,	degranulation	and	integrin	αIIbβ3	upregulation28.	Together,	these	observations	highlight	a	potential	role	for	PXR	ligands	in	regulating	GPVI-receptor	signalling.				
Inhibition	of	Src	family	kinases	(SFKs)	as	a	general	mechanism	for	PXR	function.	Platelet	 function	stimulated	by	GPVI,	 integrin	αIIbβ3	and	GPCRs	 	are	all	dependent	on	signalling	via	SFKs29.	The	down-regulation	of	both	early	and	late	GPVI	signalling	events	suggested	the	involvement	of	specific	target	elements	of	PXR	ligands	in	GPVI	signalling,	facilitating	this	cascade	of	inhibition.	Given	the	down-regulation	of	Syk	phosphorylation,	these	elements	are	likely	to	act	at	a	level	that	is	upstream	of	Syk,	such	as	SFKs.	Therefore,	the	regulation	of	SFK	activity	by	PXR	ligands	was	monitored.	Treatment	with	SR12813	(Fig.	 8A)	 and	 rifampicin	 (Suppl.	 Fig.	 7A)	 (50	 and	 100	 µM)	 reduced	 CRP-XL-induced	autophosphorylation	 of	 Src	 at	 Y41830	 and	 Lyn	 at	 Y39631	 (Fig.	 8B)	 (Suppl.	 Fig.	 7B),	 in	comparison	with	vehicle	(DMSO	0.1%	v/v).	To	determine	whether	the	regulation	of	SFKs	marks	a	general	mechanism	of	action	for	PXR	ligands,	signalling	pathways	initiated	by	
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other	platelet	receptors	dependent	on	SFKs	(such	as	CLEC-2	and	integrin	αIIbβ3)	were	examined29.	
As	was	observed	with	other	platelet	agonists,	SR12813	(Suppl.	Fig.	7C)	and	rifampicin	(Suppl.	 Fig.	 7D)	 were	 found	 to	 attenuate	 platelet	 aggregation	 stimulated	 by	 CLEC-2	agonist	 rhodocytin	 (100	 nM).	 Consistent	 with	 this,	 SR12813	 (Fig.	 8C)	 and	 rifampicin	(supplemental	 Fig.	 7E)	 were	 also	 able	 to	 significantly	 diminish	 rhodocytin	 (100	 nM)	induced	 Src	 phosphorylation	 (Y418).	 The	 stimulation	 time	 with	 rhodocytin	 was	enhanced	(120	secs)	to	detect	phosphorylation	considering	the	long	lag-phase	associated	with	 the	 initiation	 of	 rhodocytin-evoked	 platelet	 aggregation.	 To	 further	 support	 a	general	 role	 for	 PXR	 ligand-dependent	 down-regulation	 of	 SFK	 activity,	 Src	phosphorylation	was	also	found	to	be	attenuated	in	platelets	treated	with	SR12813	(Fig.	8D),	 following	 adhesion	 to	 fibrinogen	 (100	 µg/ml).	 Interestingly,	 no	 alteration	 in	 Src	phosphorylation	 was	 observed	 in	 rifampicin-treated	 samples	 (supplemental	 Fig.	 7F).	This	 might	 be	 attributed	 to	 the	 experimental	 challenges	 of	 examining	 signalling	stimulated	by	fibrinogen	under	static	conditions.	Altogether	these	findings	suggest	that	PXR	ligands	potentially	mediate	their	inhibitory	effects	on	platelet	function	via	the	down-regulation	of	SFKs	activity.	
	
Discussion	Platelets	 are	 vital	 therapeutic	 targets	 for	 the	 treatment	 of	 cardiovascular	 diseases	including	 atherothrombosis32.	 Current	 treatment	 includes	 the	 usage	 of	 anti-platelet	drugs/therapies	that	prevent	platelet	activation	by	inhibiting	different	platelet	signalling	pathways33.	 These	 treatment	 regimens	 are	 effective,	 however,	 numerous	 side-effects	(such	 as	 bleeding	 and	 drug	 resistance)	 limit	 their	 successful	 use34.	 Therefore,	 the	
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development	of	newer	strategies	with	minimal	side-effects	is	required.	NRs	expressed	in	platelets	have	been	proposed	to	exhibit	antithrombotic	effects35.	In	this	study,	we	report	the	expression	of	PXR	in	platelets	and	the	ability	of	its	ligands	to	regulate	platelet	function	and	thrombosis.		
Acute	effects	of	PXR	ligands	were	investigated,	noting	that	the	principal	ligands	for	this	receptor	required	high	concentrations	(10-100	µM	for	this	study)	to	elicit	acute	biological	effects36.	 It	 is	 reported	 that	 the	 ligands	 that	 activate	 PXR	 require	 micromolar	concentrations,	generally	two	to	three	orders	of	magnitude	higher	than	concentrations	found	circulating	in	plasma36	and	lower	than	the	concentrations	used	in	this	study.	Sub-micromolar	concentrations	of	PXR	ligands	are	sufficient	to	elicit	genomic	effects	through	regulation	of	gene	expression	in	nucleated	cells.	Notably,	the	work	presented	here	reveals	the	 non-genomic	 effects	 of	 these	 ligands	 in	 anucleated	 platelets.	 Given	 the	 likely	differences	in	the	mechanism	of	genomic	and	non-genomic	functions	of	NRs,	 including	PXR,	 it	 is	 not	 possible	 to	 directly	 compare	 features	 of	 these	 responses	 such	 as	 EC50.	Indeed,	our	group	has	previously	shown	that	NRs	(such	as	PPARg,	LXR,	RXR,	and	FXR)	in	platelets	regulate	non-genomic	functions	that	are	distinct	from	genomic	regulation2,4-6,35.	Genomic	effects	of	NRs	are	usually	determined	via	cell-based	reporter	assays	that	involve	exposing	 transcription	 factors	 (such	 as	 PXR)	 to	 their	 ligands	 for	 prolonged	durations	(hours	or	days)37,38,	 	whereas	the	time	frame	in	which	non-genomic	effects	are	elicited	ranges	from	a	few	seconds	to	a	few	minutes	and	appears	to	require	acute	exposure	to	higher	 concentrations	 of	NR	 ligands39.	 Further	work	will	 be	 required	 to	 establish	 the	molecular	basis	of	PXR	and	other	NRs	in	platelets.	
Treatment	of	platelets	with	PXR	 ligands	 resulted	 in	attenuation	of	multiple	aspects	of	platelet	 activation	 including	 aggregation,	 integrin	 αIIbβ3	 activation	 and	 granule	
20 
 
secretion.	 A	 trend	 of	 inhibition	 (although	 non-significant)	 was	 observed	 at	 low	concentrations	(10	and	20	μM)	of	PXR	ligands.	This	is	relevant	as	clinical	administration	of	 rifampicin	 (600mg)	 to	 treat	 tuberculosis	 can	 achieve	 such	 peak	 plasma	 levels40-42.	Increasing	the	acute	treatment	time	of	platelets	with	PXR	ligands	was	found	to	enhance	the	anti-platelet	effects	of	PXR	ligands	and	as	such	further	work	is	needed	to	determine	the	effects	of	chronic	exposure	to	low	concentrations	of	PXR	ligands	on	platelet	activity	and	thrombosis.			
In	 platelets,	 apart	 from	 PXR,	 RXR	 also	 interacts	 with	 LXR6,	 PPARα6	 and	 PPARγ6,19,	although,	the	role	of	such	heterodimers	in	non-genomic	functions	is	unclear	and	requires	further	 investigation.	 Platelets	 possess	mRNA,	 capable	 of	 undergoing	 a	minor	 level	 of	translation43.	Recently	RARα	was	identified	to	regulate	protein	synthesis	to	some	extent	by	its	binding	to	a	subset	of	mRNAs	in	human	platelets44.	Hence,	it	is	possible	that	other	NRs	including	PXR	(in	a	bound	or	unbound	state	with	RXR)	may	also	contribute	to	some	level	of	protein	translation	even	in	the	absence	of	a	nucleus45,46.	To	date,	we	have	found	no	evidence	to	indicate	the	formation	of	NR	homodimers	in	platelets.					
PXR	 ligands	 down-regulated	 CRP-XL-mediated	 calcium-mobilisation	 and	 activation	 of	PKC.	This	observation	 coupled	with	 the	previously	 reported	abilities	of	PPARγ2,	RXR6,	LXR5	and	FXR4	ligands	to	modulate	calcium-mobilisation	identifies	a	potentially	common	and	 fundamental	 role	 of	 NR	 ligands	 in	 regulating	 calcium	 homeostasis	 in	 platelets.	 In	addition	to	PXR,	other	NRs	such	as	LXR5	and	PPARγ2	have	also	been	identified	to	regulate	the	 GPVI	 signalling	 pathway,	 whereas	 RXR6,	 PPARα1,	 PPARβ47	 and	 FXR4	 function	 by	modulating	cyclic	nucleotide	signalling	in	platelets.	This	suggests	that	platelet	NRs	have	overlapping	and	distinct	mechanisms	of	action	in	platelets35.		
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The	 inhibition	 of	 CRP-XL-induced	 downstream	 signalling	 events	 in	 platelets	 was	identified	 to	 be	 an	 outcome	 of	 reduced	 phosphorylation	 of	 SFKs	 (Src	 and	 Lyn),	 key	regulators	 of	 upstream	 signalling	 events.	 Besides	 GPVI,	 SFKs	 regulate	 signalling	downstream	of	several	other	platelet	 receptors	 that	 include	 integrin	αIIbβ3	and	α2β1,	CLEC-2,	 FcRγIIA	 and	 GPIb-IX-V	 receptor	 and	 therefore	 play	 a	 fundamental	 in	 platelet	activation29.	SR12813	treatment	negatively-regulated	Src	phosphorylation,	proximal	 to	integrin	 αIIbβ3,	 which	 ensures	 thrombus	 stability	 via	 the	 regulation	 of	 outside-in	signalling.	The	mechanism	by	which,	PXR	regulates	the	phosphorylation	of	SFKs	requires	further	exploration.	Given	the	ability	of	NRs	such	as	LXR5	and	PPARγ2	to	bind	with	key	signalling	molecules	of	the	GPVI	pathway	and	modulate	signalling,	it	is	possible	that	PXR	follows	a	similar	mechanism	and	interacts	with	one	or	more	GPVI	signalling	components	to	 regulate	 signalling.	 However,	 the	 interaction	 of	 PXR	 with	 SFKs,	 Syk,	 LAT	 or	 PLCγ	downstream	 of	 GPVI	was	 not	 observed	 in	 this	 study.	 There	 remains	 a	 range	 of	 other	potential	 points	 of	 interaction	 to	 explore	 such	 as	 the	 GPVI/FcRγ	 complex	 that	 might		facilitate	this	effect.	Consistent	with	the	inhibition	of	GPVI	signalling,	thrombus	formation,	both	in	vitro	and	in	vivo	was	found	to	be	reduced	considerably,	which	might	be	a	combined	outcome	of	reduced	activity	of	SFKs	downstream	of	GPVI,	α2β1,	GPIb-V-IX	and	integrin	αIIbβ3.	 Furthermore,	 Src	 phosphorylation	 was	 also	 attenuated	 by	 PXR	 ligands,	downstream	 of	 CLEC-2,	 which	 provides	 additional	 evidence	 that	 PXR	 ligands	 broadly	affect	the	activity	of	SFKs	in	multiple	signalling	pathways	and	thus	elicit	their	effects.	
PXR	is	naturally	promiscuous	with	its	activating	ligands	representing	a	diverse	array	of	structurally	different	compounds.	However,	this	promiscuity	is	also	specific	in	nature	as	its	activators	can	structurally	differ	from	non-activators	by	only	a	few	atoms,	suggesting	that	 PXR	 binds	 to	 a	 diverse	 but	 precise	 array	 of	 compounds,	 a	 feature	 referred	 to	 as	
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“directed	promiscuity”48.	In	this	study,	we	also	devised	strategies	to	rule	out	non-specific	effects	 of	 PXR	 ligands.	 Firstly,	 we	 used	 two	 different	 PXR	 ligands	 (SR12813	 and	rifampicin)	that	have	the	highest	affinity	towards	this	receptor	and	are	also	structurally	distinct	from	each	other.	In	addition	to	this,	PXR	ligands	demonstrated	species-specific	responses	to	PXR	ligands.	Human	or	mouse	PXR	ligands	did	not	affect	mouse	or	human	platelet	activation	(as	demonstrated	via	integrin	aIIbb3	activation	and	in	vitro	thrombus	formation	assays)	respectively,	while	human	PXR	ligands	significantly	inhibited	human	platelets	and	mouse	PXR	ligands	reduced	mouse	platelet	activation.	This	is	plausible	only	when	the	effects	of	PXR	ligands	are	mediated	via	PXR.	While	systemic	knock-out	models	are	ideal	to	test	the	specificity	of	ligands,	in	many	circumstances,	deletion	of	transcription	factors	 can	 lead	 to	 far-reaching	 effects	 on	 cell	 biogenesis	 and	 their	 functions,	 due	 to	potential	effects	on	the	expression	of	many	proteins.	It	is	for	this	reason	that	humanised	PXR	mice	were	used	in	this	study.		In	this	study,	the	use	of	PXR	antagonists	was	avoided,	since	most	NR	antagonists	are	characterised	as	such	due	to	their	effects	on	the	regulation	of	 gene	 expression.	 Since	 the	 effects	 of	 NR	 agonists	 on	 platelets	 are	 mediated	 by	alternative,	non-genomic	mechanisms,	and	noting	our	previous	observation	that	some	NR	 antagonists	 (e.g.	 RXR)	 exert	 similar	 effects	 on	 platelets	 to	 respective	 receptor	agonists6,	 we	 anticipated	 that	 this	 approach	 may	 produce	 a	 confusing	 picture.	 This	reinforced	our	decision	to	explore	the	mode	of	action	of	PXR	ligands	in	platelets	using	a	genetic	approach	in	mice.	
In	summary,	our	study	demonstrates	the	anti-thrombotic	properties	of	PXR	ligands.		In	addition	to	the	already	identified	anti-atherosclerotic	effects	of	PXR15-17,	these	findings	suggest	the	potential	use	of	PXR	as	a	cardio-protective	drug	target.		PXR	ligands	were	also	associated	with	 impaired	haemostasis	 and	 therefore	 their	 potential	 development	 into	
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effective	therapeutic	agents	would	require	careful	balancing	of	anti-platelet	effects	and	bleeding	risk.		
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FIGURE	LEGENDS		
	
Figure	1.	PXR	is	present	 in	human	platelets.	 (A)	PXR	was	 immunoprecipitated	(IP:	PXR)	from	human	platelets	(IP:	PXR)	using	a	mouse	monoclonal	antibody	and	blotted	with	a	rabbit	polyclonal	antibody.	Human	whole	platelet	lysates	(WPL)	and	antibody	used	to	IP	(Ab:	PXR)	PXR	were	used	as	positive	and	negative	controls,	respectively.	Cropped	western	blot	image	is	representative	of	3	separate	experiments	using	different	donors.	Full	length	blot	is	shown	in	supplementary	 figure	 8A	 (B)	 The	 localisation	 of	 PXR	 in	 human	 resting	 platelets	 was	investigated	 using	 immunofluorescence	 microscopy.	 PXR	 (in	 red)	 and	 membrane	 GPIb	receptors	(in	green)	were	stained	using	anti-PXR	and	anti-GPIb	antibodies.	Platelets	without	primary	antibody	treatment	were	used	as	negative	controls.	(C)	Flow	cytometry	was	used	to	examine	the	median	fluorescence	level	of	PXR	in	permeabilised	resting	and	activated	(with	0.1	U/ml	thrombin)	human	platelets,	incubated	with	a	PXR	antibody	or	the	equivalent	rabbit	IgG	isotype	 control.	 (D)	Median	 fluorescence	 intensity	 (MFI)	 associated	 with	 the	 PXR	 positive	platelets	 in	 resting	 and	 activated	 platelets.	 Data	 represent	 mean±SD	 (N≥3),	 *P˂0.05	 was	calculated	by	Student	T-test.	Figure	adapted	from	corresponding	PhD	thesis49.	
	
	
Figure	 2.	 PXR	 and	 RXR	 interact	 and	 co-localise	 in	 human	 platelets.	 (A)	 RXR	 was	immunoprecipitated	from	human	washed	platelets	(8x108	cells/ml)	using	a	mouse	monoclonal	anti-RXR	antibody.	Immunoblot	analysis	was	followed	with	the	addition	of	a	rabbit	polyclonal	anti-PXR	 antibody	 and	 its	 detection	 using	 a	 secondary	 antibody	 that	 does	 not	 recognize	denatured	 IgG.	 The	 presence	 of	 RXR	 was	 also	 confirmed	 in	 the	 same	 samples.	 Cropped	representative	blot	 of	3	 separate	 experiments	 is	 shown.	Full	 length	blot	of	PXR	and	RXR	 is	shown	in	supplementary	figure	8Bi	and	8Bii	respectively	(B)	Localisation	of	PXR	and	RXR	in	resting	and	activated	(with	5	µM	U46619	in	the	presence	of	integrelin)	permeabilised	human	platelets	was	investigated	using	immunofluorescence	microscopy.	RXR	(in	red),	PXR	(in	blue)	and	membrane	GPIb	receptors	(in	green)	were	stained	using	anti-RXR,	anti-PXR	and	anti-GPIb	antibodies	respectively.	Representative	figures	show	the	distribution	of	RXR	and	PXR	in	resting	and	activated	platelets.	(C)	Scatter	plots	between	the	fluorescence	intensity	points	of	RXR	and	PXR	in	resting	and	activated	platelets	represent	the	degree	of	colocalisation	between	RXR	and	PXR.	(D)	The	Pearson	correlation	coefficient	(PCC)	representing	the	degree	of	colocalisation	between	RXR-PXR	in	resting	and	activated	platelets.	PCC	was	quantified	for	12	platelets	using	different	fields.	Data	represent	mean±SD,	**P˂0.01	and	***P˂0.001	was	calculated	by	Student	T-test.	Figure	adapted	from	corresponding	PhD	thesis49.	
	
	
Figure	 3.	 SR12813	 inhibits	 platelet	 aggregation,	 integrin	 αIIbβ3	 activation	 and	
secretion.	Human	washed	 platelets	 (4x108	 cells/ml)	 pre-treated	with	 SR12813	 or	 vehicle-control	(DMSO,	0.1%	v/v)	were	stimulated	with	(A,	B)	collagen	(EC50:	0.5-0.8	µg/ml)	or	(C)	thrombin	(EC50:	0.03-0.04	U/ml).	Representative	aggregation	traces	are	shown.	Quantified	data	displays	the	percentage	of	aggregation	(vehicle-treated	samples	represent	100%	aggregation)	at	the	end	of	5	minutes.	(D)	Human	PRP	treated	with	SR12813	or	vehicle	for	10	minutes	was	
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stimulated	 with	 CRP-XL	 (EC50:	 0.25	 µg/ml)	 or	 thrombin	 (EC50:	 0.05	 U/ml)	 and	 fibrinogen	binding	to	integrin	αIIbβ3	was	measured	using	flow	cytometry.	(E)	P-selectin	expsosure	was	measured	 in	SR12813	treated	PRP,	stimulated	with	CRP-XL	(0.25	µg/ml)	or	thrombin	(0.05	U/ml).	Vehicle-treated	control	is	defined	as	100%	fibrinogen	binding	and	P-selectin	exposure.	ATP	release	was	monitored	for	5	minutes	in	washed	platelets	(4x108	cells/ml),	incubated	with	SR12813	or	 vehicle-control	 for	 20	mins	 and	 stimulated	with	 (F)	 collagen	 (1	 µg/ml)	 or	 (G)	thrombin	(0.05	U/ml).	Representative	traces	and	quantified	data	are	shown.	Vehicle-treated	samples	represent	100%	ATP	secretion.	(H)	TxB2	production	was	evaluated	in	human	washed	platelets	 (4x108	 cells/ml)	 pre-incubated	 with	 SR12813	 or	 vehicle	 control	 for	 20	 min	 and	stimulated	 by	 CRP-XL	 (1	 μg/ml)	 or	 thrombin	 (0.05	 U/ml)	 for	 5	 minutes.	 Data	 represent	mean±SD	(n≥3),	*P˂0.05,	**P˂0.01	and	***P˂0.001	was	calculated	by	one-way	ANOVA.	Figure	adapted	from	corresponding	PhD	thesis49.	
	
	
Figure	 4.	 PXR	 ligands	 function	 in	 a	 species-specific	 manner	 and	 inhibit	 thrombus	
formation	in	vitro.	Human	or	mouse	PRP	was	treated	with	(A)	SR12813	or	(B)	PCN	or	vehicle-control	(0.1%	DMSO	v/v	for	SR12813	or	0.5%	v/v	DMSO	for	PCN)	prior	to	stimulation	with	CRP-XL	 (0.25	 µg/ml	 for	 human	 platelets	 and	 0.5	 µg/ml	 for	 mouse	 platelets).	 The	 level	 of	fibrinogen	binding	to	integrin	αIIbβ3	was	measured	using	flow	cytometry.	Human	or	mouse	blood,	 incubated	 with	 DiOC6	 (5	 μM)	 were	 perfused	 through	 collagen-coated	 (100	 μg/ml)	microfluidic	chips	at	arterial	flow	rate	(20	dyne/cm2)	after	treatment	with	(C,	D)	SR12813	or	
(E,	F)	PCN	or	vehicle-control	(0.1%	DMSO	v/v	for	SR12813	or	0.5%	v/v	DMSO	for	PCN)	for	20	minutes.	Representative	images	display	thrombus	formation.	Quantified	data	represent	mean	thrombus	fluorescence	intensity	normalised	to	fluorescence	level	of	the	vehicle-treated	sample	obtained	 at	 the	 end	 of	 the	 assay.	Data	 represent	mean±SD	 (n≥3)	where	 *P˂0.05,	 **P˂0.01,	***P˂0.001	 and	 ****P˂0.0001	 was	 determined	 by	 student	 t-test	 or	 one-way	 ANOVA	 for	fibrinogen	binding	assay	and	two-way	ANOVA	for	 in	vitro	 thrombus	formation	assay.	Figure	adapted	from	corresponding	PhD	thesis49.	
	
	
Figure	5.	SR12813	inhibit	thrombosis	and	haemostasis.	Laser-induced	injury	model	was	used	 to	 measure	 thrombosis	 in	 hPXR	 mice	 through	 intravital	 microscopy.	 Vehicle-control	(DMSO	0.1%	v/v)	or	SR12813	(100	μM)	was	administered	intravenously	to	mice	and	incubated	for	 20	 minutes.	 Platelets	 were	 labelled	 with	 Alexa488–conjugated	 anti-GPIb	 antibody.	 (A)	Representative	 images	 of	 thrombi	 obtained	 at	 different	 time	 intervals.	 (B)	 Data	 represent	median	fluorescence	intensity,	measured	for	8	to	10	thrombi	from	3	mice	each	of	control	and	SR12813	 treated	 groups.	 (C)	 Thrombus-size	 was	 calculated	 using	 area	 under	 the	 median	fluorescence	intensity	curve	of	each	thrombi.	(D)	Mean	of	maximum	fluorescence	intensity	of	the	 thrombus.	 (E)	 Tail	 bleeding	 was	 performed	 on	 hPXR	mice	 pre-treated	with	 vehicle	 or	SR12813	(100	μM)	for	20	min	(n=7).	Data	represent	mean	±	SD	(n≥3)	where	*P˂0.05,	**P˂0.01	and	***P˂0.001	was	determined	by	nonparametric	Mann–Whitney	U	test.	Figure	adapted	from	corresponding	PhD	thesis49.	
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Figure	 6.	 SR12813	 inhibit	 outside-in	 signalling	 in	 platelets.	 Human	 washed	 platelets	(2x107	cells/ml)	were	treated	with	SR12813	(50	and	100	μM)	or	vehicle-control	(DMSO	0.1%	v/v)	 for	 20	 minutes	 and	 added	 onto	 (A)	 fibrinogen	 (100	 μg/ml)	 or	 (C)	 collagen-coated	coverslips	for	45	mins.	Platelets	were	stained	using	Alexa-Fluor	488	for	visualisation	using	a	Nikon	A1-R	confocal	microscope	(100X).	5	images	were	captured	of	each	sample	at	random	locations.	Representative	 images	of	platelet	adhesion	and	spreading	are	shown.	Cumulative	data	of	platelets	 adhered	 in	 each	 sample	 is	 shown.	 Spreading	platelets	were	divided	 into	3	classes:	(adhered	but	not	spread;	filopodia:	spreading	platelets	and	lamellipodia:	fully	spread).	Results	expressed	(as	relative	 frequency)	as	 the	percentage	of	 the	total	number	of	platelets	adhered.	(B)	Human	PRP	was	incubated	with	SR12813	(20,	50	and	100	μM)	or	vehicle-control	(DMSO	0.1%	v/v)	for	20	minutes.	Extent	of	clot	retraction	was	determined	by	comparing	clot	weight	after	60	minutes.	Representative	image	of	clot	retraction	after	the	end	of	the	assay	is	shown.	 Cumulative	 data	 represent	 clot	 weight	 (in	 mg)	 of	 samples	 treated	 with	 SR12813	compared	 with	 vehicle-control.	 Data	 represent	 mean±SD	 (n≥3),	 *P˂0.05,	 **P˂0.01	 and	***P˂0.001	 was	 calculated	 by	 one-way	 ANOVA.	 Figure	 adapted	 from	 corresponding	 PhD	thesis49.	
	
	
Figure	 7.	 SR12813	 negatively	 regulate	 GPVI-mediated	 signalling.	 Platelets	 (4x108	cells/ml)	were	pre-treated	with	vehicle	(DMSO	0.1%	v/v)	or	SR12813	(0,	50	and	100	μM)	for	20	 minutes	 and	 stimulated	 with	 CRP-XL	 (1	 μg/ml)	 for	 90	 seconds	 in	 the	 presence	 of	indomethacin	(20	μM),	cangrelor	(1	μM),	MRS2179	(100	μM)	and	EGTA	(1	mM).	Samples	were	tested	for	(A)	Total	tyrosine,	(B)	Syk	(Y525/526),	(C)	LAT	(Y200),	(D)	PLCγ2	(Y1217)	and	(F)	PKC	 substrate	 phosphorylation.	 Representative	 immunoblots	 are	 shown.	 Levels	 of	phosphorylation	 were	 quantified	 and	 expressed	 as	 a	 percentage	 of	 untreated	 (vehicle)	controls.	 14-3-3-ζ	 or	 actin	 was	 used	 as	 a	 loading	 control.	 Full	 length	 blots	 are	 shown	 in	supplementary	figure	9		(E)	Calcium	mobilisation	was	evaluated	in	Fura-2AM	loaded	platelets	(4x108	cells/ml)	incubated	with	SR12813	(50	and	100	μM)	or	vehicle-control	(DMSO	0.1%	v/v)	for	20	min	prior	to	stimulation	with	CRP-XL	(0.25	μg/ml).	Traces	of	CRP-XL-stimulated	calcium	mobilisation	over	a	period	of	5	minutes	are	shown.	Cumulative	data	(peak	calcium	levels)	of	calcium	mobilisation.	Data	 represent	mean±SD	 (n≥3)	where	 *P˂0.05,	 **P˂0.01,	 ***P˂0.001	and	****P˂0.0001	was	determined	by	One-way	ANOVA.	Figure	adapted	from	corresponding	PhD	thesis49.	
	
	
Figure	8.	SR12813	inhibit	tyrosine	phosphorylation	of	SFKs	proximal	to	GPVI,	CLEC-2	
and	 integrin	 αIIbβ3	 receptors.	 Platelets	 (4x108	 cells/ml)	 were	 pre-treated	 with	 vehicle-control	(DMSO	0.1%	v/v)	or	SR12813	(0,	50	and	100	μM)	for	20	minutes	and	stimulated	for	
(A,	B)	90	seconds	with	CRP-XL	(1	μg/ml)	or	(C)	120	seconds	with	rhodocytin	(100	nM)	in	the	presence	of	indomethacin	(20	μM),	cangrelor	(1	μM),	MRS2179	(100	μM)	and	EGTA	(1	mM).	
(D)	 Washed	 platelets	 (4x108	 cells/ml),	 pre-treated	 with	 SR12813	 (0,	 50	 and	 100	 μM)	 or	vehicle-control	were	exposed	to	fibrinogen-coated	wells	(100	μg/ml)	of	a	tissue	culture	plate	and	 allowed	 to	 adhere	 for	 30	minutes.	 Samples	were	 tested	 for	 Src	 (Y418)	 or	 Lyn	 (Y396)	
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phosphorylation.	Representative	 immunoblots	are	 shown.	The	phosphorylation	 levels	were	quantified	and	expressed	as	a	percentage	of	untreated	(vehicle)	controls.	Actin	was	used	as	a	loading	 control.	 Full	 length	 blots	 are	 shown	 in	 supplementary	 figure	 9	 and	10.	 Results	 are	mean±SD	(n≥3),	*P˂0.05,	**P˂0.01,	***P˂0.001	and	****P˂0.0001	was	calculated	by	one-way	ANOVA.	Figure	adapted	from	corresponding	PhD	thesis49.		 	
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Methods	
Human	platelet	preparation	Human	 blood	 was	 taken	 from	 consenting,	 drug-free	 volunteers	 on	 the	 day	 of	 the	experiment	 according	 to	 the	 methodology	 approved	 by	 the	 University	 of	 Reading	Research	Ethics	Committee.	Blood	was	taken	using	3.8%	(w/v)	sodium	citrate	and	Acid	Citrate	Dextrose	(ACD;	110	mmol/L	glucose,	80	mmol/L	citric	acid,	120	mmol/L	sodium	citrate)	as	an	anticoagulant.	Whole	blood	was	centrifuged	at	102g	for	20	minutes	at	20°C	to	yield	platelet-rich	plasma	(PRP).	Where	washed	platelets	were	required,	 they	were	isolated	from	the	PRP	by	further	centrifugation	at	1413g	for	10	minutes	at	20oC	in	the	presence	of	0.1	μg/ml	prostacyclin	to	prevent	activation.	The	supernatant	was	discarded	in	 Klorsept	 disinfectant	 (Medentech,	 Wexford,	 Ireland)	 and	 the	 platelet	 pellet	 was	resuspended	in	25ml	of	modified	Tyrodes-HEPES	buffer	(134	mmol/L	NaCl,	0.34	mmol/L	Na2HPO4,	2.9	mmol/L	KCl,	12	mmol/L	NaHCO3,	20	mmol/L	HEPES,	5	mmol/L	glucose,	1	mmol/L	 MgCl2,	 pH	 7.3)	 and	 3	 ml	 of	 ACD	 in	 the	 presence	 of	 0.1	 μg/ml	 prostacyclin.	Platelets	were	centrifuged	at	1413g	for	10	minutes	at	20oC	and	resuspended	to	a	density	of	4x108	cells/ml	in	modified	Tyrodes-HEPES	buffer	using	a	platelet	count	obtained	with	a	Z	Series	Coulter	Counter	(Beckman	Coulter,	CA,	USA).	Washed	platelets	were	rested	for	at	least	30	minutes	at	30oC	prior	to	the	experiment	to	allow	responses	to	recover.	Platelet	preparations	 typically	contained	 fewer	 than	1	contaminating	erythrocyte	or	 leukocyte	per	6500	platelets.	ADP-sensitive	 washed	 platelets	 were	 prepared	 by	 collecting	 blood	 into	 3.8%	 (w/v)	sodium	citrate	and	centrifugation	at	102g	for	20	minutes	at	20oC	to	yield	PRP	(without	the	addition	of	ACD).	Platelets	were	isolated	from	the	PRP	by	further	centrifugation	at	350g	 for	 20	minutes.	 The	 supernatant	was	 discarded,	 and	 the	 platelet	 pellet	was	 re-suspended	to	a	density	of	4x108	cells/ml	in	modified	Tyrodes-HEPES	buffer.		
Immunofluorescence microscopy Human	 blood	 was	 collected	 in	 vacutainers	 containing	 sodium	 citrate	 as	 described	previously.	The	blood	was	centrifuged	at	100g	for	20	minutes	to	collect	PRP.	Resting	or	activated	platelets	(stimulated	with	5	µM	U46619;	in	the	presence	of	4	µM	integrillin)	in	PRP	were	fixed	with	an	equal	volume	of	8%	paraformaldehyde-PBS	(PFA-PBS)	to	make	a	final	 concentration	 of	 4%	 (v/v)	 and	 incubated	 for	 15	min.	 Thereafter,	 platelets	were	centrifuged	at	950g	 for	10	minutes.	The	supernatant	was	removed,	and	platelet	pellet	was	resuspended	in	2	ml	of	PBS-ACD	(pH	6.1)	for	washing.	Platelets	were	centrifuged	for	10	 minutes	 at	 950g	 and	 resuspended	 in	 1	 ml	 of	 PBS-ACD	 to	 concentrate	 platelets.	Platelets	were	centrifuged	again	at	the	same	speed	for	10	minutes	and	then	resuspended	in	500µl	of	1%	(w/v)	BSA-PBS,	to	concentrate	platelets	even	more.	Poly-L-lysine	coated-12mm	coverslips	(VWR	micro	cover	glass	No.1.5)	were	put	in	6x6	culture	plate	and	90μl	of	 platelets	were	 added	 on	 each	 coverslip.	 Culture	 plates	were	 placed	 at	 37oC	 for	 90	
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minutes.	After	2-3	washes	with	PBS,	samples	were	blocked	with	0.2%	(v/v)	Triton-X-100,	2%	(v/v)	serum	from	same	species	as	secondary	antibody	and	1%	(w/v)	protease-free	BSA	 for	 1h.	 Thereafter,	 anti-PXR	 and	 anti-GPIb	 primary	 antibodies	 diluted	 (1:100)	 in	0.2%	(v/v)	Triton-X-100,	2%	(v/v)	serum	from	the	same	species	as	secondary	antibody	and	 1%	 (w/v)	 protease-free	 BSA	 were	 added	 and	 left	 overnight.	 The	 following	 day,	samples	 were	 washed	 with	 PBS	 (2-3	 times)	 and	 secondary	 antibodies	 (1:200)	 were	added	for	1	hour	at	room	temperature.	The	unbound	antibodies	were	washed	off	with	PBS	 (2-3	 times)	 and	 samples	were	 fixed	 using	 4%	 (v/v)	 PFA-PBS	 for	 5	minutes.	 The	coverslips	were	washed	 again	with	 PBS	 (2-3	 times).	 Coverslips	were	 placed	 on	 glass	slides	after	adding	ProLong	Gold	Antifade	mounting	media	(Life	technologies).	The	slides	were	kept	at	room	temperature	until	mounting	media	dried	and	then	kept	in	the	fridge	until	they	were	imaged	using	a	Nikon	A1-R	confocal	microscope	(100x	oil	immersion).		
Platelet aggregometry Light	 transmission	 aggregometry	 (LTA)	 was	 performed	 in	 an	 optical	 platelet	aggregometer	 (Chrono-Log,	 PA,	 USA,	 and	Helena	Biosciences	 Europe,	 Gateshead,	 UK).	Washed	platelets	(4x108	cells/ml)	were	stimulated	in	the	presence	of	agonist	(collagen,	CRP-XL,	thrombin,	U46619	or	ADP)	with	continuous	stirring	(1200	rpm	at	37oC)	for	5	minutes	and	aggregation	was	measured	as	an	increase	in	light	transmittance.	The	effects	of	PXR	 ligands	on	platelet	aggregation	were	measured	by	 incubating	washed	platelets	with	PXR	ligand	dissolved	in	DMSO	(final	DMSO	concentration	in	sample	of	0.1%	v/v)	or	vehicle	control	(containing,	DMSO	0.1%	v/v)	for	10	or	20	minutes	prior	to	the	addition	of	agonist.	 The	 data	 was	 quantified	 by	 considering	 vehicle-treated	 samples	 as	 100%	aggregation	and	the	level	of	aggregation	obtained	in	PXR	treated	samples	was	normalised	to	it.		
	 	 	
Fibrinogen	binding	and	alpha	granule	secretion		Fibrinogen	 binding	 and	 P-Selectin	 exposure	 were	 measured	 using	 FITC-conjugated	polyclonal	rabbit	anti-human	fibrinogen	antibody	and	PE/Cy5	mouse	anti-human	CD62P	antibody,	respectively,	in	a	96-well	flat	bottom	plate.	PRP	was	treated	with	PXR	ligands	or	 vehicle	 control	 for	 10	 minutes	 (containing,	 DMSO	 0.1%	 v/v).	 1	 μl	 each	 of	 anti-fibrinogen	and	anti-CD62P	antibody	was	added	per	50	μl	sample	prior	to	stimulation	with	agonists	(CRP-XL	or	thrombin)	for	20	minutes	with	occasional	gentle	mixing.	GPRP	(25	μg/ml)	was	added	in	samples	stimulated	with	thrombin	to	prevent	fibrin	polymerization.	Reactions	were	stopped	by	adding	0.2%	(w/v)	formyl	saline.	Analyses	were	performed	by	flow	cytometry	using	a	BD	Accuri	C6	flow	cytometer	(BD	Biosciences,	Oxford,	UK),	and	data	were	collected	from	10,000	events	[gated	on	platelets	using	FSC	(forward	scatter,	limited	between	1520-16000000)	and	SSC	(side	scatter,	limited	between	152-1600000)]	and	analysed	using	inbuilt	BD	Accuri	C6	plus	software,	version	1.0.264.21.	
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Measurement	of	PXR	in	platelets	using	flow	cytometry	To	measure	 PXR	within	 platelets,	 resting	 and	 activated	 (with	 1	 µg/ml	 CRP-XL	 in	 the	presence	of	integrilin)	human	washed	platelets	(200	µl)	at	4x108	cells/mL	were	fixed	by	adding	an	equal	volume	2%	(w/v)	formyl	saline	and	permeabilised	using	400	µl	of	BD	Phosflow	Perm	Buffer	III	(BD	Bioscience,	Oxford,	UK)	for	1	h	in	ice.	Platelets	were	then	incubated	with	 rabbit	 anti-PXR	 primary	 antibody	 (SantaCruz;	 sc-25381)	 for	 an	 hour.	Following	washing	at	550g	for	20	min,	platelets	were	resuspended	in	HEPES	buffer	saline.	Thereafter,	 platelets	 were	 incubated	 with	 an	 appropriate	 secondary	 Cy5-conjugated	antibody	 (Invitrogen,	 Paisley	 UK)	 for	 an	 hour.	 Negative	 controls	 were	 set	 using	 an	appropriate	 isotype	 control.	 Analyses	were	 performed	 by	 flow	 cytometry	 using	 a	 BD	Accuri	C6	 flow	cytometer	 (BD	Biosciences,	Oxford,	UK),	 and	data	were	 collected	 from	10,000	 events	 [gated	 on	 platelets	 using	 FSC	 (forward	 scatter,	 limited	 between	 1520-16000000)	and	SSC	 (side	scatter,	 limited	between	152-1600000)]	and	analysed	using	inbuilt	BD	Accuri	C6	plus	software,	version	1.0.264.21.		
Dense granule secretion Secretion	of	ATP	from	dense	Granule	upon	platelet	agonist	stimulation	was	measured	in	washed	platelets	(4x108	cells/ml)	using	a	Lumi-aggregometer	(model	700,	Chronolo-Log,	PA,	USA)	 (Feinman	 et	 al.,	 1977).	Washed	platelets	were	 added	 to	 a	 glass	 cuvette	 and	incubated	 with	 the	 Chronolume	 reagent	 for	 2	 minutes,	 while	 stirring	 using	 the	aggregometer.	2	nM	ATP	was	added	to	this	stirred	suspension	of	platelets	to	set	the	ATP	response	 baseline.	 The	 luminescence	 increase	 was	 observed	 using	 the	 AggroLink	 8	software	 (Chrono-Log,	 PA,	 USA),	 with	 the	 luminescent	 gain	 adjusted	 until	 the	 ATP	response	was	within	the	manufacturer-instructed	range	of	20-60%.	These	settings	were	saved	 and	 used	 for	 the	 rest	 of	 the	 experiment.	 Thereafter,	 washed	 platelets	 were	incubated	with	PXR	ligands	or	vehicle	control	(containing,	DMSO	0.1%	v/v)	at	37°C	for	20	minutes	under	non-stirring	conditions.	2	minutes	prior	the	end	of	incubation	period,	Chronolume	reagent	was	added	and	stirred	using	 the	aggregometer.	Washed	platelets	were	then	stimulated	by	the	addition	of	agonist	(collagen	or	thrombin)	and	the	baseline	was	 set.	 ATP	 release	 from	 dense	 granule	 was	 recorded	 for	 5	 minutes	 following	 the	addition	of	agonist	using	the	AggroLink	8	software,	which	calculates	ATP	secretion	levels	from	the	2nM	ATP	standard.		
 
Measurement of intracellular calcium mobilisation 
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PRP	was	incubated	with	Dual	excitation	dye	(at	340	and	380	nm),	Fura-2AM	(2	µM)	for	1	hour	at	30oC	and	was	 followed	by	centrifugation	at	350g	 for	20	minutes.	The	platelet	pellet	was	resuspended	in	modified	Tyrodes-HEPES	buffer	(4x108	cells/ml).	Thereafter,	Fura-2	AM	loaded	washed	platelets	were	incubated	with	PXR	ligands	or	vehicle	control	(containing,	DMSO	0.1%	v/v)	for	10	minutes	at	37oC	prior	to	addition	of	platelet	agonists	(CRP-XL	 or	 thrombin).	 Fluorescence	 measurements	 (excitation	 340	 and	 380	 nm,	emission	 510	 nm)	were	 recorded	 for	 5	minutes	 (1	measurement	 every	 1.5s)	 using	 a	NOVOstar	plate	reader.	[Ca2+]i	was	estimated	by	using	the	ratio	of	the	340	nm	and	380	nm	 excited	 signals.	 Calibration	was	 performed	 by	 treating	 an	 untreated	 sample	with	digitonin	 (50	µM)	to	 lyse	 the	platelets,	which	releases	 the	Fura-2AM	into	 the	Tyrodes	buffer,	 containing	CaCl2	(2	mM),	 allowing	measurement	of	 the	maximum	 fluorescence	ratio.	To	calculate	the	minimum	fluorescence	ratio,	Ca2+	ions	were	chelated	by	addition	of	10	mM	ethylene	glycol-bis(b-aminoethyl	ester)-N,N,N’,N’-tetraacetic	acid	(EGTA)	and	10	mM	TRIS	base	(added	to	ensure	an	alkaline	pH	for	optimal	Ca2+	buffering	by	EGTA).	Auto-fluorescence	was	measured	using	unloaded	platelets.	Using	these	calibration	values	(maximum,	minimum	and	autofluorescence),	experimental	[Ca2+]i	concentrations	were	calculated	using	the	following	equation:	
[𝐶𝑎$%]' = 	𝐾+ 	×	 𝑆.𝑆/ 	×	 𝑅 − 𝑅2'3𝑅245 − 𝑅	Where	Kd	is	the	dissociation	constant	of	Fura-2AM	(~224	nM).	Sf	and	Sb	are	the	values	of	the	fluorescence	at	380nm	excitation	(corrected	to	background	auto-fluorescence),	with	zero	or	saturating	[Ca]2+	respectively.	R	is	the	340/380nm	fluorescence	ratio,	corrected	for	background	fluorescence.	Rmin	and	Rmax	are	the	ratio	limits	at	zero	or	saturating	[Ca]2+,	respectively,	adjusted	using	a	viscosity	constant	of	0.85.	This	corrects	for	the	effects	of	the	cellular	environment	on	the	fluorescence	of	Fura-2.		
 
Platelet adhesion and spreading Glass	coverslips	were	placed	in	6	well	plates	and	coated	with	collagen	or	fibrinogen	(100	
µg/ml	each)	(in	modified	PBS)	for	1	hour.	1%	(w/v)	BSA	was	then	added	onto	coverslips	and	incubated	for	1	hour	to	prevent	platelets	binding	to	the	glass.	The	coverslips	were	washed	3	times	with	PBS.	Washed	platelets	at	a	density	of	2x107	cells/ml	were	treated	with	PXR	ligand	or	vehicle	control	(containing,	DMSO	0.1%	v/v)	for	20	minutes,	and	then	added	onto	coverslips	and	incubated	for	45	minutes	at	37oC.	The	supernatant	was	then	removed	from	the	coverslips,	which	were	again	washed	3	times	with	PBS.	Platelets	were	then	 fixed	with	0.2%	 (w/v)	paraformaldehyde	 (PFA)	 for	10	minutes,	 the	 supernatant	removed,	 and	coverslips	washed	3	 times	with	PBS.	Platelets	were	 then	permeabilised	with	0.2%	(v/v)	Triton-X-100	for	5	minutes,	and	then	the	supernatant	was	removed	and	coverslips	washed	3	times	again	with	PBS.	Alexa-Fluor	488	phalloidin	was	then	added	
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onto	 the	coverslips	 for	1	hour,	 incubated	 in	 the	dark,	 to	 label	platelet	F	 (filamentous)	actin.	The	supernatant	was	removed,	and	coverslips	washed	3	times	with	PBS.	Coverslips	were	 then	mounted	 onto	 slides	with	 the	 addition	 of	 Prolong	 Gold	 Antifade	mounting	media	to	preserve	fluorescence.	Samples	were	imaged,	using	a	100X	oil	immersion	lens	on	a	Nikon	A1-R	confocal	microscope	(Nikon,	Tokyo,	Japan).	Fluorescence	was	excited	at	488	nm	with	an	argon	laser	and	emitted	at	500-520	nm,	with	images	captured	in	one	focal	plane.	Platelet	adhesion	data	were	obtained	by	counting	 the	number	of	platelets	on	5	images	of	each	coverslip	that	were	captured	randomly.	Platelets	were	scored	as	adhered	(not	 spread),	 spreading	 (defined	 as	 extending	 filopodia)	 or	 spread	 fully	 (lamellipodia	formed),	 and	 the	 relative	 frequency	 of	 each	 population	was	 determined	 using	 ImageJ	software.		
Clot retraction The	PRP	was	obtained	as	described	earlier	and	was	incubated	with	2	µl	of	PXR	ligands	or	vehicle	control	(containing,	DMSO	0.1%	v/v)	for	20	minutes.	Modified	Tyrodes-HEPES	buffer	was	added	to	test	tubes,	along	with	red	blood	cells,	to	allow	visualization	of	the	clot.	This	was	followed	by	the	addition	of	PRP	treated	with	PXR	ligand	or	vehicle	control.	Clot	formation	was	initiated	by	adding	thrombin	(final	concentration	1	U/ml)	to	the	test	tubes.	A	glass	pipette	was	added	to	the	centre	of	each	test	tube,	around	which	the	clot	would	 form,	 and	 samples	were	 placed	 in	 an	 incubator	 chamber	 at	 37oC.	 Photographs	were	taken	every	10	minutes	and	the	assay	was	terminated	after	60	minutes	at	which	time	the	clot	in	the	vehicle-treated	samples	were	seen	to	have	retracted	completely.	Clot	weight	was	measured	as	a	marker	for	clot	retraction.	Clots	were	removed	from	the	glass	pipettes	 and	 transferred	 into	 the	 pre-weighed	 microfuge	 tubes.	 Clot	 mass	 was	determined	by	subtracting	the	weight	of	pre-weighed	microfuge	tubes	from	the	weight	of	microfuge	tubes	containing	clot.				
Western blotting Human	washed	platelets	were	prepared	at	a	density	of	8x108	cells/ml	as	described	earlier	and	 lysed	 by	 adding	 6X	 Laemmli	 sample	 reducing	 buffer	 [4%	 (w/v)	 SDS,	 20%	 (v/v)	glycerol,	0.5M	Tris,	0.001%	(w/v)	Brilliant	Blue	R	and	10%	(v/v)	2-mercaptoethanol].	Samples	were	heated	to	95oC	for	5	minutes	before	storing	at	-20oC	until	use.		To	 study	 cell	 signalling,	human	washed	platelets	were	prepared	at	 a	density	of	4x108	cells/ml	 under	 non-aggregation	 conditions	 [indomethacin	 (20	 µM),	 cangrelor	 (1	 µM),	MRS2179	(100	µM)	and	EGTA	(1	mM).	These	platelets	were	treated	with	PXR	ligands	or	vehicle	control	(containing	DMSO,	0.1%	v/v)	 for	20	minutes	and	then	stimulated	with	platelet	agonists	 in	 the	aggregometer.	Unstimulated	or	stimulated	samples	were	 lysed	
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with	6X	Laemmli	sample	reducing	buffer	and	heated	to	95oC	for	5	minutes	before	storing	at	-20oC	until	use.	Proteins	were	separated	by	SDS-PAGE	as	described	previously	by	Laemmli	(1970),	using	10%	or	4-20%	Mini-PROTEAN	TGX	precast	protein	gels.	Samples	were	heated	to	95oC	for	5	minutes	again	prior	to	loading	into	gels,	which	were	submerged	in	1X	Tris/Glycine/SDS	buffer	(25	mM	Tris,	192	mM	glycine,	0.1%	SDS,	pH	8.3)	within	a	Mini-PROTEAN	tetra	vertical	electrophoresis	cell	(Bio-Rad,	CA,	USA).	Electrophoresis	was	run	for	45	minutes	or	1	hour	at	a	constant	voltage	of	150V.	The	separated	proteins	on	gels	were	transferred	to	a	polyvinylidene	difluoride	(PVDF)	membrane	 using	 semi-dry	 western	 blotting	 (Trans-Blot	 SD	 Semi-Dry	 Transfer	 Cell;	BioRad,	CA,	USA).	A	single	piece	of	PVDF	membrane	soaked	in	methanol	was	placed	below	the	resolving	gel	in	the	transfer	cell.	This	arrangement	of	gel	and	PVDF	membrane	was	sandwiched	between	4	sheets	of	3MM	filter	paper	soaked	in	cathode	buffer	(25	mM	Tris-base,	40	mM	6-amino-N-hexanoic	acid;	pH	9.4)	placed	at	the	top	and	4	sheets	of	3MM	filter	paper	soaked	in	anode	buffer	(300	mM	Tris-base,	20%	(v/v)	methanol;	pH	10.4)	placed	at	the	bottom.	A	constant	voltage	of	15V	was	applied	to	this	setup	for	2	hours	to	facilitate	efficient	transfer	of	proteins	from	gel	to	membrane.	PVDF	 membranes	 were	 then	 transferred	 into	 a	 5%	 (w/v)	 solution	 of	 bovine	 serum	albumin	(BSA)	dissolved	in	Tris-buffered	saline	with	Tween	20	(TBS-T)	(20	mM	Tris,	140	mM	NaCl,	0.1%	Tween,	pH	7.6)	to	block	the	membrane	for	1	hour	at	room	temperature.	Primary	antibodies	were	added	into	a	2%	(w/v)	solution	of	BSA	(dissolved	in	TBS-T)	and	membranes	were	incubated	with	these	solutions	overnight	at	4oC	on	a	rotator.	Primary	antibody	 solutions	 were	 removed	 from	 the	 PVDF	 membranes	 the	 next	 day	 and	membranes	 were	 washed	 three	 times	 for	 10	 minutes	 each	 with	 TBS-T.	 Secondary	antibodies	were	added	to	a	2%	(w/v)	BSA	(dissolved	in	TBS-T)	solution,	which	was	then	added	to	PVDF	membranes	and	incubated	in	the	dark	at	room	temperature	for	1	hour.	PVDF	membranes	were	washed	three	times	again	for	5	minutes	each	with	TBS-T.	PVDF	membranes	 were	 scanned	 using	 a	 Typhoon	 FLA	 9500	 (Amersham	 Biosciences,	Buckinghamshire,	 UK),	 and	 quantification	 of	 the	 fluorescence	 intensity	 of	 individual	bands	was	determined	using	Image	Quant	software	version	8.1	(GE	healthcare).		
 
Immunoprecipitation Washed	human	platelets	were	prepared	(8x108	cells/ml)	as	described	previously.	Cells	were	lysed	on	ice	using	an	equal	volume	of	2X	NP40	buffer	(300	mM	NaCl,	20	mM	Tris,	10	 mM	 EDTA,	 2%	 v/v	 NP40;	 pH=7.3)	 containing	 protease	 inhibitors	 [Leupeptin	 (10	µg/ml),	 aprotinin	 (10	 µg/ml),	 phenylmethylsulphonyl	 fluoride	 (1	 mM)	 sodium	orthovanadate	(1mM)	and	pepstatin-A	(25	µg/ml)].	The	lysed	platelets	in	NP40	buffer	
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(1X)	were	incubated	with	primary	antibody	and	Protein	A/G	magnetic	beads	(20	μl	per	500	 µl	 of	 lysate)	 at	 4°C	 overnight.	 The	 following	 day,	 the	 beads	 were	 collected	 in	Eppendorf	 tube	 using	 a	 magnetic	 stand	 and	 washed	 twice	 with	 NP40	 buffer	 (1X)	containing	protease	 inhibitors	 and	once	with	TBST.	Thereafter,	 100	μl	 of	 2X	Laemmli	sample	reducing	buffer	was	added	to	the	beads.	The	samples	were	then	heated	to	95°C	for	5	minutes	and	kept	at	-20°C	for	use	in	Western	blotting.			
In vitro thrombus formation under flow Human	or	mouse	whole	blood	was	 incubated	 at	30oC	with	5	µM	of	 the	 lipophilic	dye	DiOC6	for	1	hour.	Microfluidic	channels	(Cellix,	Dublin,	Ireland)	were	coated	with	type	I	collagen	 (100	 µg/ml)	 for	 one	 hour	 and	 excess	 collagen	 was	 washed	 with	 modified	Tyrodes-HEPES	buffer.	Whole	blood	was	incubated	with	PXR	ligands	or	vehicle	control	(containing,	 DMSO	 0.1%	 v/v	 DMSO)	 for	 20	 minutes	 prior	 to	 perfusion	 through	 the	collagen-coated	microfluidic	channels	at	an	arteriolar	shear	stress	of	20	Dyne/cm2	(shear	rate:	 500	 s-1).	 Fluorescence	was	 excited	 at	 488	 nm	with	 an	 argon	 laser	 and	 emission	detected	at	500-520	nm.	The	thrombus	formation	on	the	microfluidic	chip	was	observed	using	a	Nikon	A1-R	confocal	microscope	with	a	20X	objective	and	images	(focused	on	a	single	 section)	 were	 captured	 every	 1	 second	 for	 600	 seconds.	 Mean	 thrombus	fluorescence	intensity	was	calculated	using	NIS	Elements	software	(Nikon,	Tokyo,	Japan).			
In vivo thrombus formation The	 mice	 were	 anaesthetised	 by	 intraperitoneal	 injection	 of	 ketamine	 (125	 mg/kg),	xylazine	(12.5	mg/kg)	and	atropine	(0.25	mg/kg).	Anaesthesia	was	maintained	with	5	mg/kg	pentobarbital	as	and	when	required.	The	cremaster	muscle	was	exteriorized	and	the	connective	tissue	removed,	after	which	an	incision	was	made,	allowing	the	cremaster	muscle	 to	 be	 affixed	 over	 a	 glass	 slide	 as	 a	 single	 sheet;	 the	muscle	 preparation	was	hydrated	 throughout	 with	 buffer	 (135mM	 NaCl,	 4.7mM	 KCl,	 2.7mM	 CaCl2,	 18mM	NaHCO3,	pH	7.4).	SR12813,	vehicle	control	(containing,	DMSO	0.1%	v/v)	and	DyLight	649	anti-GPIba	antibody	(0.2	µg/g	mouse	weight;	for	platelet	labelling)	was	infused	into	the	mouse	circulation	through	carotid	artery	cannula	prior	to	the	injury	(performed	using	a	Micropoint	 Ablation	 Laser	 Unit;	 Andor	 Technology	 PLC,	 Belfast,	 Northern	 Ireland).	Thrombus	 formation	 was	 visualised	 after	 20	 minutes	 of	 the	 infusion	 of	 SR12813	 or	vehicle	 control	 using	 an	Olympus	BX61W1	microscope	 (Olympus	Corporation,	 Tokyo,	Japan).	The	images	were	captured	both	prior	to	and	after	the	injury,	using	a	Hamamatsu	digital	camera	C9300	(Hamamatsu	Photonics	UK	Ltd,	Hertfordshire	UK)	charge-coupled	device	 (CCD)	 camera	 in	 640	 x	 480	 format.	 Images	 were	 analysed	 using	 Slidebook	 6	software	(Intelligent	Imaging	Innovations,	CO,	USA).	Following	the	procedure,	mice	were	
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sacrificed	in	accordance	with	Home	office	licences	and	approval	from	the	University	of	Reading	local	ethics	review	panel	and	Animal	welfare	and	Ethics	Research	Board.		
Tail bleeding assay On	 the	 day	 of	 the	 experiment,	 C57/BL6	 or	 hPXR	 mice	 were	 anesthetised	 by	intraperitoneal	 injection	 of	 ketamine	 (125	 mg/kg)	 and	 xylazine	 (12.5	 mg/kg)	 and	SR12813	or	vehicle	control	(containing,	DMSO	0.1%	v/v)	was	 injected	via	the	femoral	vein.	 20	 minutes	 later,	 the	 tail	 tip	 was	 removed	 with	 a	 scalpel	 and	 the	 tail	 was	immediately	placed	into	tubes	containing	saline,	in	a	manner	that	prevented	the	cut	end	of	the	tail	from	contacting	the	side	of	the	tube.	The	time	of	bleeding	was	recorded	until	the	 blood	 flow	 had	 ceased.	 Following	 the	 procedure,	 or	 after	 20	minutes,	mice	were	sacrificed	in	accordance	with	Home	office	licences	and	approval	from	the	University	of	Reading	local	ethics	review	panel	and	Animal	welfare	and	Ethics	Research	Board.				
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Supplementary	figures	
Suppl.	Figure	1	
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Suppl.	figure	1.	PXR	ligands	inhibit	platelet	aggregation	to	a	range	of	agonists.	Human	washed	platelets	(4x108	cells/ml)	pre-treated	with	SR12813	or	rifampicin	or	vehicle-control	(DMSO,	0.1%	v/v)	were	stimulated	with	(A,	B)	collagen	(EC50:	0.5-0.8	µg/ml)	or	(C)	thrombin	(EC50:	 0.03-0.04	 U/ml)	 or	 (D,	 E)	U46619	 (EC50:	 0.25	 µM)	 or	 (F,	 G)	 ADP	 (EC50:	 5-10	 µM).	Aggregation	was	measured	 for	 300	 seconds.	 Representative	 aggregation	 traces	 are	 shown.	Quantified	 data	 displays	 the	 percentage	 of	 aggregation	 of	 SR12813	 or	 rifampicin	 treated	samples	(vehicle-treated	samples	represent	100%	aggregation)	at	the	end	of	5	minutes.	Data	represent	mean±SD	(n≥3),	*P˂0.05,	**P˂0.01,	***P˂0.001	and	****P˂0.0001	was	calculated	by	one-way	ANOVA.	Figure	adapted	from	corresponding	PhD	thesis	-	Non-genomic	effects	of	the	Pregnane	X	Receptor	(PXR)	and	Retinoid	X	Receptor	(RXR)	in	platelets49.	
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Suppl.	Figure	2	
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Suppl.	 figure	 2.	 Rifampicin	 attenuate	 fibrinogen	 binding	 to	 integrin	 αIIbβ3	 and	
degranulation.	(A)	Human	PRP	was	treated	with	rifampicin	or	vehicle-control	(DMSO	0.1%	v/v)	for	10	minutes	prior	to	stimulation	with	CRP-XL	(EC50:	0.25	µg/ml)	or	thrombin	(EC50:	0.05	U/ml)	and	fibrinogen	binding	to	integrin	αIIbβ3	was	measured	using	flow	cytometry.	(B)	P-selectin	was	measured	in	rifampicin	treated	PRP	and	stimulated	with	CRP-XL	(0.25	µg/ml)	or	thrombin	(0.05	U/ml).	Vehicle-treated	control	is	defined	as	100%	fibrinogen	binding	and	P-selectin	 exposure.	 (C,	D)	 Changes	 in	ATP	 release	were	monitored	 for	5	minutes	 in	washed	platelets	 (4x108	 cells/ml)	 incubated	 with	 rifampicin	 or	 vehicle-control	 for	 20	 mins	 and	stimulated	 with	 collagen	 (1	 µg/ml)	 or	 thrombin	 (0.05	 U/ml).	 Representative	 traces	 and	quantified	 data	 are	 shown.	 Vehicle-treated	 samples	 represent	 100%	 ATP	 secretion.	 (E)	Washed	platelets	(4x108	cells/ml)	pre-treated	with	saturating	concentrations	of	indomethacin	(20	 μM)	 or	 ADP	 receptor	 antagonists	 -	 cangrelor	 (1	 μM)	 and	 MRS2179	 (100	 μM)	 were	stimulated	 with	 collagen	 (10	 μg/ml)	 in	 the	 presence	 or	 absence	 of	 SR12813	 (100	 µM).	Representative	 aggregation	 trace	 recorded	 for	 5	 minutes	 is	 shown.	 Quantified	 data	 for	collagen-stimulated	platelet	aggregation	 in	 the	presence	or	absence	of	SR12813,	along	with	indomethacin	(I+SR)	or	cangrelor	and	MRS2179	(C+M+SR)	or	all	of	them	together	(C+M+I+SR).	‘O’	 signifies	 the	 sample	 stimulated	with	 collagen	 in	 the	absence	of	 SR12813	and	 secondary	mediator	 signalling	 blockers.	 Data	 represent	 mean±SD	 (n≥3),	 †P˂0.05	 and	 ††P˂0.01	 was	calculated	by	student	 t-test.	 **P˂0.01,	***P˂0.001	and	****P˂0.0001	was	calculated	by	one-way	 ANOVA.	 Figure	 adapted	 from	 corresponding	 PhD	 thesis	 -	 Non-genomic	 effects	 of	 the	Pregnane	X	Receptor	(PXR)	and	Retinoid	X	Receptor	(RXR)	in	platelets49.	
	
	
	
	
	
	
	
	
	
	
	
	
	
52 
 
Suppl.	Figure	3	
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Suppl.	 figure	 3.	 PXR	 ligands	 inhibit	 thrombus	 formation	 in	 vitro.	 (A)	 Human	 blood	incubated	with	DiOC6	(5	μM)	was	perfused	through	collagen-coated	(100	μg/ml)	microfluidic	chips	at	an	arterial	flow	rate	(20	dyne/cm2)	after	treatment	with	rifampicin	or	vehicle-control	(DMSO	 0.1%	 v/v)	 for	 20	 minutes.	 Representative	 images	 display	 thrombus	 formation.	Quantified	data	represent	mean	thrombus	fluorescence	intensity	normalised	to	fluorescence	level	of	the	vehicle-treated	sample	obtained	at	the	end	of	the	assay.	The	expression	levels	of	
(B)	α2β1,	(C)	αIIbβ3,	(D)	GPIb,	and	(E)	GPVI	were	analysed	on	resting	and	CRP-XL-stimulated	(1	μg/ml)	platelets	from	hPXR	and	C57BL/6	wild-type	mice	by	flow	cytometry.	Data	represent	mean±SD	(n≥3)	where	**P	≤	0.01,	***P˂0.001	and	****P˂0.0001	was	determined	by	two-way	ANOVA	(in	vitro	thrombus	formation)	and	Student	t-test	(flow	cytometry).	Figure	adapted	from	corresponding	 PhD	 thesis	 -	 Non-genomic	 effects	 of	 the	 Pregnane	 X	 Receptor	 (PXR)	 and	Retinoid	X	Receptor	(RXR)	in	platelets49.	
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Suppl.	Figure	4	
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Suppl.	 figure	 4.	 Rifampicin	 inhibit	 outside-in	 signalling	 in	 platelets.	 Human	 washed	platelets	 (2x107	cells/ml)	were	 treated	with	 rifampicin	 (50	and	100	μM)	or	vehicle-control	(DMSO	0.1%	v/v)	for	20	minutes	and	added	onto	(A)	fibrinogen	(100	μg/ml)	or	(C)	collagen-coated	coverslips	for	45	mins.	Platelets	were	stained	using	Alexa-Fluor	488	for	visualisation	using	a	Nikon	A1-R	confocal	microscope	(100X).	5	 images	were	captured	of	each	sample	at	random	 locations.	 Representative	 images	 of	 platelet	 adhesion	 and	 spreading	 are	 shown.	Cumulative	data	of	platelets	adhered	in	each	sample	is	shown.	Spreading	platelets	were	divided	into	3	classes:	(adhered	but	not	spread;	filopodia:	spreading	platelets	and	lamellipodia:	fully	spread).	Results	expressed	(as	relative	 frequency)	as	 the	percentage	of	 the	 total	number	of	platelets	 adhered.	 (B)	 Human	 PRP	 was	 incubated	 with	 SR12813	 (20,	 50	 and	 100	 μM)	 or	vehicle-control	(DMSO	0.1%	v/v)	for	20	minutes.	Extent	of	clot	retraction	was	determined	by	comparing	clot	weight	after	60	minutes.	Representative	image	of	clot	retraction	after	the	end	of	the	assay	is	shown.	Cumulative	data	represent	clot	weight	(in	mg)	of	samples	treated	with	SR12813	compared	with	vehicle-control.	Data	represent	mean±SD	(n≥3),	*P˂0.05,	**P˂0.01	and	***P˂0.001	was	calculated	by	one-way	ANOVA.	Figure	adapted	from	corresponding	PhD	thesis	-	Non-genomic	effects	of	the	Pregnane	X	Receptor	(PXR)	and	Retinoid	X	Receptor	(RXR)	in	platelets49.	
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Suppl.	Figure	5	
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Suppl.	 figure	 5.	 Human	 PXR	 ligands	 does	 not	 regulate	 cyclic	 nucleotide	 mediated	
signalling	in	platelets.	Human	washed	platelets	(4x108	cells/ml)	were	tested	for	(A)	VASP	S157	and	(B)	VASP	S239	phosphorylation	in	samples	treated	with	SR12813	or	rifampicin	(0,	50	and	100	μM)	or	vehicle	(DMSO	0.1%	v/v)	for	20	min.	PGI2	and	PAPANOATE	(NO	donor),	which	upregulates	the	activity	of	PKA	and	PKG	were	included	as	positive	controls.	14-3-3-ζ	was	used	 as	 a	 loading	 control.	 Full	 length	 blots	 are	 shown	 in	 supplementary	 figure	 11.	Representative	 blots	 from	 3	 different	 experiments	 are	 shown.	 Figure	 adapted	 from	corresponding	 PhD	 thesis	 -	 Non-genomic	 effects	 of	 the	 Pregnane	 X	 Receptor	 (PXR)	 and	Retinoid	X	Receptor	(RXR)	in	platelets49.	
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Suppl.	Figure	6	
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Suppl.	 figure	 6.	 Rifampicin	 negatively	 regulates	 GPVI-mediated	 signalling.	 Platelets	(4x108	cells/ml)	were	pre-treated	with	vehicle	(DMSO	0.1%	v/v)	or	rifampicin	(0,	50	and	100	μM)	for	20	minutes	and	stimulated	with	CRP-XL	(1	μg/ml)	for	90	seconds	in	the	presence	of	indomethacin	(20	μM),	cangrelor	(1	μM),	MRS2179	(100	μM)	and	EGTA	(1	mM).	Samples	were	tested	for	(A)	Total	tyrosine,	(B)	Syk	(Y525/526),	(C)	LAT	(Y200),	(D)	PLCγ2	(Y1217)	and	(F)	PKC	 substrate	 phosphorylation.	 Representative	 immunoblots	 are	 shown.	 Levels	 of	phosphorylation	 were	 quantified	 and	 expressed	 as	 a	 percentage	 of	 untreated	 (vehicle)	controls.	 14-3-3-ζ	 or	 actin	 was	 used	 as	 a	 loading	 control.	 Full	 length	 blots	 are	 shown	 in	supplementary	figure	9	(E)	Calcium	mobilisation	was	evaluated	in	Fura-2AM	loaded	platelets	(4x108	cells/ml)	incubated	with	rifampicin	(50	and	100	μM)	or	vehicle-control	(DMSO	0.1%	v/v)	for	20	min	prior	to	stimulation	with	CRP-XL	(0.25	μg/ml).	Traces	of	CRP-XL-stimulated	calcium	mobilisation	 over	 a	 period	 of	 5	minutes.	 Cumulative	 data	 (peak	 calcium	 levels)	 of	calcium	 mobilisation.	 Data	 represent	 mean±SD	 (n≥3)	 where	 *P˂0.05,	 **P˂0.01	 and	***P˂0.001was	 determined	 by	 one-way	 ANOVA.	 Figure	 adapted	 from	 corresponding	 PhD	thesis	-	Non-genomic	effects	of	the	Pregnane	X	Receptor	(PXR)	and	Retinoid	X	Receptor	(RXR)	in	platelets49.																			
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Suppl.	figure	7	
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Suppl.	 figure	7.	Rifampicin	 inhibit	 tyrosine	phosphorylation	of	 SFKs.	Washed	platelets	(4x108	cells/ml)	were	pre-treated	with	vehicle-control	(DMSO	0.1%	v/v)	or	rifampicin	(0,	50	and	100	μM)	for	20	minutes	and	stimulated	for	(A,	B)	90	seconds	with	CRP-XL	(1	μg/ml)	or	
(E)	120	seconds	with	rhodocytin	(100	nM)	in	the	presence	of	indomethacin	(20	μM),	cangrelor	(1	μM),	MRS2179	 (100	μM)	and	EGTA	 (1	mM).	(F)	Washed	platelets	 (4x108	 cells/ml),	pre-treated	with	 rifampicin	 (0,	 50	 and	100	μM)	or	 vehicle-control	were	 exposed	 to	 fibrinogen-coated	wells	(100	μg/ml)	of	a	tissue	culture	plate	and	allowed	to	adhere	for	30	minutes.	The	samples	were	tested	for	Src	(Y418)	or	Lyn	(Y396)	phosphorylation.	Representative	blots	for	the	 phosphorylation	 levels	 are	 shown.	 The	 phosphorylation	 levels	 were	 quantified	 and	expressed	as	a	percentage	of	untreated	(vehicle)	controls.	Actin	was	used	as	a	loading	control.	
(C,	D)	 Rhodocytin	 (100	nM)	 induced	platelet	 aggregation	was	measured	 in	human	washed	platelets	(4x108	cells/ml)	pre-treated	with	SR12813	or	rifampicin	or	vehicle-control	(DMSO,	0.1%	v/v).	Aggregation	was	measured	for	300	seconds.	Representative	aggregation	traces	are	shown.	 Quantified	 data	 displays	 the	 percentage	 of	 aggregation	 of	 SR12813	 or	 rifampicin	treated	samples	(vehicle-treated	samples	represent	100%	aggregation)	at	the	end	of	2	minutes,	3	 minutes	 and	 5	 minutes.	 Full	 length	 blots	 are	 shown	 in	 supplementary	 figure	 9	 and	supplementary	 figure	 10.	 Results	 are	 mean±SD	 (n≥3),	 *P˂0.05,	 **P˂0.01,	 ***P˂0.001	 and	****P˂0.0001	was	 calculated	 by	 one-way	ANOVA.	 Figure	 adapted	 from	 corresponding	 PhD	thesis	-	Non-genomic	effects	of	the	Pregnane	X	Receptor	(PXR)	and	Retinoid	X	Receptor	(RXR)	in	platelets49.	
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Suppl.	figure	8	
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Suppl.	figure	8.	(A)	Full	blot	image	of	figure	1A.	PXR	was	immunoprecipitated	(IP:	PXR)	from	human	platelets	 (IP:	PXR),	which	was	 followed	with	a	western	blot	 analysis.	Human	whole	platelet	 lysates	 (WPL)	 and	 antibody	 used	 to	 IP	 (Ab:	 PXR)	 PXR	 were	 used	 as	 positive	 and	negative	 controls,	 respectively.	 (Bi,	 Bii)	 Full	 blot	 image	 of	 figure	 2A.	 RXR	 was	immunoprecipitated	from	human	washed	platelets.	 Immunoblot	analysis	was	followed	with	the	addition	of	an	anti-PXR	antibody	and	its	detection	using	a	secondary	antibody	that	does	not	recognize	denatured	IgG.	The	presence	of	RXR	was	also	confirmed	in	the	same	samples.																								 			 	
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Suppl.	figure	9	
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Suppl.	figure	9.	Platelets	were	pre-treated	with	vehicle	(DMSO	0.1%	v/v)	or	SR12813	(0,	50	and	 100	 μM)	 for	 20	minutes	 and	 stimulated	with	 CRP-XL	 (1	 μg/ml)	 for	 90	 seconds	 in	 the	presence	of	indomethacin	(20	μM),	cangrelor	(1	μM),	MRS2179	(100	μM)	and	EGTA	(1	mM).	Samples	were	tested	for	Syk	(Y525/526),	LAT	(Y200),	PLCγ2	(Y1217)	and	Src.	(A)	Full	blot	image	 of	 figure	 7B	 and	 supplementary	 figure	 6B.	 (B)	 Full	 blot	 image	 of	 figure	 7C	 and	supplementary	figure	6C.	(C)	Full	blot	image	of	figure	7D.	(D)	Full	blot	image	of	supplementary	figure	6D.	(E)	Full	blot	image	of	figure	8A.	(F)	Full	blot	image	of	supplementary	figure	7A.	Blots	were	reprobed	with	actin	antibody	to	verify	equivalent	levels	of	protein	loading.					
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Suppl.	figure	10	
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Suppl.	 figure	 10.	 Platelets	 were	 pre-treated	 with	 vehicle-control	 (DMSO	 0.1%	 v/v)	 or	SR12813	(0,	50	and	100	μM)	for	20	minutes	and	stimulated	for	90	seconds	with	CRP-XL	(1	μg/ml)	or	120	seconds	with	rhodocytin	(100	nM)	in	the	presence	of	indomethacin	(20	μM),	cangrelor	(1	μM),	MRS2179	(100	μM)	and	EGTA	(1	mM).	Samples	were	tested	for	Lyn	(Y396),	or	Src	(Y418).	(A)	Full	blot	image	of	figure	8B.	(B)	Full	blot	image	of	supplementary	figure	7B.	
(C)	 Full	 blot	 image	 of	 figure	 8C.	 (D)	 Full	 blot	 image	 of	 supplementary	 figure	 7E.	Washed	platelets,	pre-treated	with	SR12813	(0,	50	and	100	μM)	or	vehicle-control	were	exposed	to	fibrinogen-coated	wells	 (100	μg/ml)	of	 a	 tissue	 culture	plate	 and	allowed	 to	 adhere	 for	30	minutes.	Samples	were	tested	for	Src	(Y418)	phosphorylation.	(E)	Full	blot	image	of	figure	8D.	
(F)	Full	blot	 image	of	 supplementary	 figure	7F.	Blots	were	reprobed	with	actin	or	14-3-3-ζ	antibody	to	verify	equivalent	levels	of	protein	loading.																							 	
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Suppl.	figure	11	
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Suppl.	 figure	 11.	 Human	 washed	 platelets	 were	 tested	 for	 VASP	 S157	 and	 VASP	 S239	phosphorylation	in	samples	treated	with	SR12813	or	rifampicin	(0,	50	and	100	μM)	or	vehicle	(DMSO	0.1%	v/v)	for	20	min.	PGI2	and	PAPANOATE	(NO	donor),	which	upregulates	the	activity	of	PKA	and	PKG	were	included	as	positive	controls.	(A)	Full	blot	image	of	supplementary	figure	5A.	(B)	Full	blot	image	of	supplementary	figure	5B.	(C)	Full	blot	image	of	supplementary	figure	5C.	 (D)	 Full	 blot	 image	 of	 supplementary	 figure	 5D.	 Blots	 were	 reprobed	 with	 14-3-3-ζ	antibody	to	verify	equivalent	levels	of	protein	loading.	
	
